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It is estimated that more than 1.7 million nosocomial infections and 98,000 deaths occur 
annually in the U.S. Nosocomial infections are associated with a longer length of stay (LOS), 
which is in-turn associated with higher costs and is a risk factor for additional infections. 
Infection prevention measures may allow a significant number of cases to be averted, although 
consensus has not been reached about the ultimate epidemiologic and economic value of 
prevention strategies. A multifaceted program of nosocomial infection prevention evaluating the 
surveillance test attributes, target population, and intervention implementation has potential to 
both improve patient outcomes and reduce healthcare costs. I developed models to evaluate and 
estimate the impact of these infection control interventions. First, testing adult hospital inpatients 
has the potential to prevent transmission of MRSA among patients. However, policy makers and 
hospital administrators must consider the diagnostic test used in a screening program. Increasing 
the number of anatomic sites tested with surveillance cultures does not appear to have as great an 
impact as decreasing turnaround time on the economic value of a MRSA testing strategy. 
Second, weekly surveillance of neonates in the neonatal intensive care unit (NICU) and isolation 
of those who test positive is a technique that hospitals could use to decrease the incidence on 
nosocomial infections, selecting neonates as a target population where MRSA infections have 
substantial morbidity. Hospitals with moderate to high adherence to isolation protocols have the 
potential to prevent adverse clinical outcomes and mortality among NICU populations. Third, 
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routine dispensing of home-based preoperative chlorhexidine bathing kits has the potential to 
prevent post-operative surgical site infections (SSIs). Our model suggests that preoperative 
bathing would have substantial economic value throughout a wide range of intervention 
implementation scenarios: patient compliance levels, cloth efficacies, costs, and SSI-attributable 
LOS, supporting the distribution of chlorhexidine cloths preoperatively. The public health 
significance is that decision makers can use the models described here to benchmark the test 
characteristics, potential target populations, and intervention implementation strategies to utilize 
in local infection prevention programs. A comprehensive approach including the interventions 
modeled here may help move towards the elimination of healthcare acquired infections. 
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1.0  INTRODUCTION 
Substantial preventable nosocomial infection attributable morbidity and mortality occur 
each year in the United States and globally.1 It is estimated that more than 1.7 million 
nosocomial infections occur annually in U.S. hospitals with more than 98,000 nosocomial deaths 
per year.2 Infections that are acquired during a patient’s stay as a result of exposure to infection 
agents within a healthcare setting are classified as nosocomial infections. These infections were 
neither present nor known to be incubating on admission and can be either systemic or 
localized.2 Nosocomial infections are often classified by anatomic site at which they occur or the 
causative agent of infection. Surgical site infections account for approximately 20% of all 
nosocomial infections in the United States.2 According to the National Healthcare Safety 
Network (NHSN), the pooled mean number of central line associated bloodstream infections 
(CLABSI) in adult medical inpatient wards was 1.5 per 1,000 central line days.3 Before 2005, 
NHSN was three distinct nosocomial infection surveillance systems: the National Nosocomial 
Infections System (NNIS), the Dialysis Surveillance Network (DSN) and National Surveillance 
System for Healthcare Workers (NaSH).3  
Nosocomial infections are associated with a longer length of stay (LOS) in the hospital, 
which in turn is associated with higher costs and can be a risk factor for the occurrence of 
additional infections.4 Nosocomial infections affect patients of all ages, from neonates to adult 
elective surgery patients, to older adults in long-term care facilities.5-7 The emergence of 
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multidrug resistant organisms (MDROs) has brought increased attention to nosocomial infections 
due to the limited antibiotic treatment options.5 The second and third line treatments for these 
infections often have lower efficacy, are more toxic resulting in side effects for patients, and tend 
to be much more expensive than first line antibiotic treatments.8 In fact, the Centers for Disease 
Control and Prevention (CDC) reports that more than 70% of hospital-acquired bacterial 
infections are resistant to at least one of the most common drugs used to treat them.8 Moreover, 
patients with MDRO infections may have delayed appropriate antibiotic treatment, increasing 
patient morbidity and healthcare costs.9 Delayed treatment has also been established as an 
independent predictor of infection-related mortality.10 
The economic burden of nosocomial infections can be assessed from different payer 
perspectives. Each perspective includes the costs that are relevant to decision makers from that 
perspective. Four major perspectives are used to conduct economic evaluations of healthcare 
interventions: 1. Hospital perspective 2. Third party payer perspective 3. Patient perspective      
4. Societal perspective. Hospital administrators and executives may be interested in determining 
the burden of nosocomial infections from the hospital perspective. The direct costs of 
hospitalization such as infection attributable excess length of stay including intensive care unit 
stay, diagnostic testing, antimicrobial treatment, healthcare worker time, and isolation supplies 
(i.e., gloves, gowns, and masks for contact isolation or private rooms for respiratory isolation) 
are the only costs included from the hospital perspective.11 Third party payers, such as insurance 
companies, also have a vested interest in the costs of nosocomial infections. Assessing the 
economic burden of nosocomial infections from the third party payer perspective includes both 
inpatient and outpatient expense. Direct medical costs (excluding isolation supplies) are 
accounted for as well as outpatient costs such as clinic visits, antimicrobial therapy, 
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rehabilitation visits as well as home health visits.11 Performing economic evaluations from the 
third party payer perspective is important because payers can have a pivotal role in establishing 
which therapies are reimbursed.  
The patient perspective is a third important perspective to consider when performing 
economic evaluations of healthcare interventions. Patients are often responsible for bearing at 
least a portion of the cost of their medical care and are also involved in making treatment 
decisions with their doctors. From the patient perspective all direct medical costs (both inpatient 
and outpatient) are accounted for as well as lost wages and travel expenses. Some have suggested 
that the cost of death may also be included when evaluating an intervention from the patient 
perspective.11 Finally, economic evaluations can be performed from the societal perspective 
which is the most inclusive perspective accounting for the costs of disease to society. The 
societal perspective includes all direct inpatient and outpatient medical costs, lost wages, travel 
expenses, the cost of death, and in the case of nosocomial infections also accounts for the 
decreased effectiveness of antimicrobial agents overall, and further increases in antimicrobial 
resistance.11 Each perspective appeals to a different set of decision makers who are evaluating 
the impact of nosocomial infection prevention measures.  
Methicillin-resistant Staphylococcus aureus (MRSA) is a nosocomial pathogen of 
particular importance due to its substantial attributable morbidity and mortality. S. aureus is 
commonly found on the skin and in the nares of healthy individuals. Carriers of S. aureus are 
asymptomatic but are able to transmit S. aureus to others. Data from the 2001-2002 National 
Health and Nutrition Examination Survey (NHANES) found that the prevalence of colonization 
with any strain of S. aureus in the nares was 31.6% and that intranasal MRSA colonization 
prevalence was 0.84%.12 NHANES data from 2002-2003 showed a statistically significant 
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decline (P<0.01) in the prevalence of S. aureus colonization to 28.6% compared to the 2001-
2002 data, although there was an increase in MRSA prevalence to 1.5% (P<0.05).13 This sample 
of the noninstitutionalized U.S. population >1 year old illustrates that S. aureus colonization is a 
prevalent commensal organism. Population estimates by Kuehnert and colleagues, also using the 
2001-2002 NHANES data, for S. aureus colonization were 89.4 million individuals (95% 
confidence interval (CI): 84.8-94.1 million people).14 MRSA colonization was estimated to be 
present in 2.3 million people in the United States (95% CI: 1.2-3.8 million MRSA 
colonizations).14 Colonization prevalence was found to vary by age and was significantly higher 
in 6-11 year olds (p<0.001) than in the reference group of 1-5 year olds, and tended to decrease 
as age increased after age 11.14 Multivariate analyses found that MRSA colonization was 
associated with being a woman older than 60 when the reference group was men 1-19 years 
old.14 However it is unclear why this study utilized different age stratification schemes for 
univariate versus multivariate analyses. S. aureus heterogeneously impacts different genders, 
race/ethnicities, and ages of people. It is estimated that approximately 60% of the population is 
intermittent carriers of MRSA. These individuals are colonized for variable durations with 
strains of S. aureus that change over a period of time.15 Persistent carriers account for 
approximately 20% of the population are colonized with the same strain of S. aureus that does 
not appear to change over time.15 The remaining portion of the population appears to be 
noncarriers of S. aureus and these people are never known to be colonized with any strains of S. 
aureus.15 The host factors that contribute to which category an individual may fall into have not 
been well studied and further research is needed. 
The Active Bacterial Core surveillance (ABCs)/Emerging Infections Program Network 
uses active population-based surveillance to estimate the annual incidence of invasive MRSA 
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infections of nine sites in the U.S. that includes more than 16.5 million individuals 
(approximately 5.6% of the U.S. population).16-17 This system utilizes regular contact with the 
hospital laboratories that confirm MRSA diagnoses to capture data regarding the incidence of 
invasive MRSA infections unlike passive surveillance systems that rely on physicians reporting 
cases of disease to public health officials. The catchment area from 2004-2008 includes the 
following sites: 1. State of Connecticut 2. Atlanta, Georgia metropolitan area 3. San Francisco 
Bay area, California 4. Denver, Colorado metropolitan area 5. Portland, Oregon metropolitan 
area 6. Monroe County, New York 7. Baltimore City, Maryland 8. Davidson County, Tennessee 
9. Ramsey County, Minnesota. From July 2004 through December 2005 the standardized 
incidence rate of invasive infections was 31.8 per 100,000 (range 24.4 to 35.2 per 100,000, 
excluding the outlier site, Baltimore City).16 The estimated number of invasive MRSA infections 
in the U.S. during this period was 94,360 (interval estimate 72,850-104,000) and an estimated 
18,650 (interval estimate 10,050-22,100) MRSA deaths.16 More recent data, from 2005 to 2008 
noted a statistically significant 9.4% per year decrease in the number of invasive hospital-onset 
MRSA infections.17 This decrease was observed in both hospital-onset and healthcare-associated 
community onset disease.17 However, from 2005 through 2008 morbidity was substantial with 
more than 21,000 invasive infections occurring in the study population, making MRSA an 
important pathogen to study.17 
Nosocomial infection prevention measures may allow a significant number of MRSA 
cases to be averted. Consensus has yet to be reached about the ultimate epidemiologic and 
economic value of various MRSA prevention strategies.18 Because the majority of individuals 
with MRSA are asymptomatically colonized, these individuals are a potential reservoir for 
transmission within a healthcare setting.19-25 Active surveillance for MRSA colonization of all 
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individuals in a healthcare setting (i.e., within a single ward such as the intensive care unit (ICU) 
or across all admissions to an acute care hospital) has been suggested as infection control 
strategy.26-31 In this context, active surveillance is systemic testing of a defined population of 
individuals in a healthcare setting to identify those individuals who are asymptomatic carriers of 
MRSA. Debate remains over which surveillance method should be used: polymerase chain 
reaction (PCR) or culture based surveillance. PCR allows for rapid surveillance results in 
approximately one hour whereas culture based surveillance takes 18-48 hours.32 Turnaround time 
can impact how quickly infection control personnel are able to implement isolation measures 
and/or decolonization. Sensitivity and specificity of different laboratory assays can vary 
dramatically; a recent study found that the sensitivity of various commercial culture-based assays 
can range from 81-93% for MRSA Select® to 96-100% for CHROMagar MRSA®.32 Specificity 
of culture based methods was shown to range from 69-87% for Brilliance MRSA Agar® to 98-
99% for BBL-CHROMagar®.32 Cost is also a consideration when choosing a surveillance 
method. The Centers for Medicare & Medicaid Services (CMS) reimburses only $12.34 for 
culture based testing versus $50.26 for PCR, which can potentially influence the ultimate 
economic value of a surveillance strategy.33 Moreover, there can be a difference between test 
cost and reimbursement. Choosing a MRSA testing strategy is a balance of test attributes, local 
epidemiological and economic conditions and laboratory capabilities. 
Once carriers are identified, surveillance must be paired with an intervention such as 
decolonization, isolation, and/or cohorting of known carriers to decrease intra-hospital 
transmission.34  Decolonization (the use of chemoprophylaxis to remove S. aureus from a 
colonized individual’s body) is another infection control strategy that often accompanies active 
surveillance.32 Debate remains over the efficacy of decolonization and if patients are to be 
 7 
decolonized, which antimicrobial agents ought to be used.35-37  Decolonization regimens often 
include intranasal mupirocin, chlorhexidine body washes and/or oral antibiotics.37 However, 
resistance to decolonization agents, such as mupirocin has been commonly documented with 
widespread use of mupirocin in the general patient population and with routine use of mupirocin 
in peritoneal dialysis patients at the nasal and hemodialysis catheter exit sites.38  
Isolation and cohorting of known MRSA carriers is a second strategy that is often used in 
conjunction with an active surveillance strategy. Rather than eliminating colonization, isolation 
strategies remove potentially infectious individuals from populations of susceptibles to minimize 
transmission within healthcare settings. Cohorting of colonized or infected individuals is used to 
prevent transmission when private rooms may not be available or in units such as the neonatal 
intensive care unit (NICU) where common rooms are the norm. Cohorting has been used in the 
NICU and long-term care facilities as a part of outbreak response.39-43 Isolation of known MRSA 
carriers is recommended by the Joint Working Party of the British Society for Antimicrobial 
Chemotherapy and the Hospital Infection Society and the Society for Healthcare Epidemiology 
of America (SHEA).44-45 SHEA also recommends decreasing unnecessary patient contact that 
may facilitate transmission of nosocomial pathogens, although a systematic review found that 
there is the potential for adverse psychological patient effects and decreased healthcare worker 
contact for patients in isolation.45-46 
Increased education of healthcare workers about MRSA transmission and proper hand 
hygiene techniques are also important tenets in most MRSA prevention and control programs.47 
Without adherence to basic infection control strategies, such as adherence to hand hygiene 
protocols, surveillance and isolation of known carriers is unlikely to be a successful strategy in 
preventing nosocomial transmission. Many nosocomial infections, including MRSA, are spread 
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by direct contact of healthcare workers and patients. Unfortunately, measuring hand hygiene 
adherence can be difficult and the quality of the evidence that increased hand hygiene causes a 
direct decrease in infection rates is of poor quality.48 Despite these limitations including 
increased hand hygiene as a part of a nosocomial infection prevention program remains an 
integral factor for a program’s ultimate success. 
Judicious use of antimicrobials as a part of an antimicrobial stewardship program is also a 
potential MRSA prevention strategy. Antimicrobial stewardship programs restrict the use of 
certain antibiotics by educating prescribers, limiting the antibiotics available on the facility’s 
formulary, and requiring preapproval for the use of antibiotics included in the stewardship 
program.49-50 Additionally, stewardship programs can incorporate antibiotic cycling, combination 
therapies, dose optimization, conversion from parenteral to oral therapy, and multidisciplinary 
teams to audit the use of antibiotics.51 These programs endeavor to eliminate unnecessary and 
suboptimal usage of antibiotics, which some studies estimate accounts for 50% of antibiotic 
usage.51-53 Debate remains over the implementation of stewardship programs because of 
difficulty of implementation and accurate measurement of the success of the programs. 
Quantifying the economic costs and benefits of such programs remains difficult despite a 
systematic review showing that stewardship programs can reduce antimicrobial resistance or 
nosocomial infection.53 Well designed prospective studies will allow a better understanding of 
the economic and epidemiologic value of stewardship programs. 
Modeling and simulation can provide insights into the economic and epidemiological 
value of nosocomial infection prevention and control strategies. Simulation models can aid in 
establishing the burden of nosocomial infections and can aid in the prioritization of different 
prevention and control measures.54 Modeling allows investigators to conduct studies that would 
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not be feasible due to cost constraints or ethical to conduct in real patient populations. For 
example, stochastic simulation models can evaluate the economic value of numerous 
preoperative screening and decolonization strategies benchmarking appropriate decolonization 
regimens, screening strategies, and costs.6, 55-56 Early in the development of vaccines for 
nosocomial infections, models can aid vaccine developers in determining appropriate target 
populations and efficacy thresholds.57-59 Models can also evaluate infection control strategies, 
such as increased environmental cleaning, staff exclusion policies when healthcare workers are 
ill, isolation of symptomatic patients, and ward closure to new admissions when there is an 
outbreak.60 Across the spectrum of infection prevention and control strategies modeling can be 
used as a complement to traditional studies. 
Data used to calibrate models relies on published epidemiological studies. These data are 
derived from studies of variable study design, sample size, and duration. Computational 
modeling can bridge gaps in the exist in the current body of literature utilizing sensitivity 
analyses to determine the potential impact of disease characteristics that are known to vary 
geographically, temporally, or among different patient populations. Retrospective cohort studies 
are often performed to better understand if there is an association between exposures of interest 
and incidence of disease or a related outcome. However, when studying nosocomial infections 
such as MRSA that have a large proportion of individuals with disease who are asymptomatic 
carriers, retrospective studies that rely on medical records for participant classification would 
likely underestimate the asymptomatic burden of disease. 
A retrospective cohort study by Allard and colleagues evaluated the changes in MRSA 
bacteremia incidence and mortality among patients at Centre Hospitalier Universitaire de 
Sherbrooke in Quebec, Canada, by reviewing medical records. MRSA bacteremia did not 
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emerge in the medical records of this hospital’s population until 2000 although the study period 
commenced  in 1991.61 Due to the retrospective design of this study it is unclear if medical 
records in this hospital did not include the combination of ICD-9 codes for MRSA due to 
hospital policies for medical record coding, a lack of susceptibility testing that is necessary to 
diagnose MRSA, or due to actual temporal changes in MRSA incidence. This study compared 
patients with MRSA to those who had MSSA. Patients with MRSA bacteremia were 
significantly older than those patients with MSSA bacteremia (45% of patients were 18-64 with 
MSSA versus 30% of patients 18-64 with MRSA, P=0.02). MRSA patients also had significantly 
higher Charlson scores than those patients with MSSA (70% of patients with MRSA had a 
Charlson score ≥4 compared to 51% of patients with MSSA, P=0.01) and patients with MRSA 
were less likely to have effective treatment administered within the first 24 hours (77% versus 
48% effectively treated for MSSA and MRSA, respectively, P<0.001). Incidence of bacteremia 
from 2000-2005 ranged from 2.6-7.4 per 100,000 residents of Sherbrooke, Quebec. Among 
sixty-nine patients with invasive bacteremia, twenty-three patients had died within 30 days of 
diagnosis (i.e., 33.3% mortality).  
A retrospective cohort study that included review of medical records by Carey et al. from 
a level III NICU of a University-affiliated Children’s Hospital in New York, New York from 
2000-2008 provided data on both the prevalence and natural history of MRSA in neonates.5 This 
hospital did not perform routine surveillance of neonates who were in-born, although they did 
perform routine surveillance of the anterior nares and preemptive isolation of neonates who were 
transferred from other facilities who accounted for 25%-30% of the NICU population. This 
sampling methodology would likely underestimate the total number of in-born asymptomatic 
carriers in the NICU. This hospital also experienced was a series of four outbreaks of MRSA 
 11 
during 2007 that led to increased MRSA testing of not only the anterior nares, but also the 
periumbilical area, axilla, and groin. During this outbreak all neonates who shared the same pod 
as an infected neonate had surveillance cultures performed. When asymptomically colonized 
neonates were identified during this outbreak all other neonates in the same wing of the NICU 
were tested for MRSA colonization.  Throughout the study period there were 98 neonatal MRSA 
infections that were utilized to calibrate the clinical MRSA infections outcomes subtree as well 
as the annual MRSA incidence. Computational models utilize the variable incidence data 
(ranging from 2 incident infections per 1,000 discharges in 2008 to 18 incident infections per 
1,000 discharges in 2002) to determine the economic and epidemiologic impact of performing 
systematic NICU surveillance under a variety of local circumstances. 
A third retrospective cohort study was also utilized to calibrate the computational models 
described in later chapters. This study that spanned seven years conducted at Brigham and 
Women’s Hospital (Boston, MA), medical records of all neonates admitted to the NICU 
throughout the study period were reviewed. Whether inborn or transferred from other facilities, 
all neonates during this period were screened on a weekly basis for MRSA with a single swab of 
both the anterior nares and then the rectum.62  Of 7,997 neonates admitted throughout the study 
period, 102 were identified as MRSA positive through screening, additionally, there were 15 
neonates who had clinical MRSA infections. There were no significant differences in birth 
history, time to positive culture, clinical status at the time of the first positive culture, or maternal 
factors in those neonates who were colonized versus those with clinical infections. Sixty-three of 
102 neonates in the study were discharged as asymptomatic MRSA carriers because the hospital 
protocol did not include decolonization. With a small sample size of neonates with clinical 
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MRSA infections, there may be questions of generalizability of the infection outcomes described 
in this study. 
Prospective cohort studies that follow a defined group of individuals forward through 
time can also be used to calibrate computational models. However, these types of studies can be 
difficult to conduct in hospital settings because patients are admitted and discharged to hospitals 
with variable lengths of stay. Moreover, prospective cohort studies can be expensive to conduct. 
Relatively few prospective cohort studies are conducted to study infections within hospital 
settings. A prospective observational study by Ellis and colleagues performed nasal screening on 
U.S. military recruits and documented the natural history of MRSA.20 On the first day of training 
of new recruits arriving at Fort Sam Houston, Texas, cultures of the anterior nares and 
demographic data were collected from all study participants. A second culture was collected 
from each recruit eight to ten weeks after the initial swab was collected to assess changes in 
colonization and infection status of the study participants over time. This population of military 
recruits was 76% male with a mean age of 21.1 years old, range 18-44 years old. Of 761 recruits 
who were sampled at both time points, 24 of 761 (3.15%) had a positive culture for MRSA at 
least one of the two samples. The prospective design of this study allowed for a point prevalence 
estimate of MRSA colonization in health young adults. Further, as a prospective cohort study, 
these investigators were able to describe changes in MRSA over a ten week period. The small 
number of individuals with MRSA and relatively short follow-up only allowed for observation of 
the most common clinical outcomes. 
Cross sectional epidemiological studies are often conducted by investigators to determine 
point prevalence of disease. Cross sectional studies are much shorter in duration than prospective 
cohort studies and are therefore less expensive. By definition, cross sectional studies provide 
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data for a more limited period of time than cohort studies and may be less generalizable for 
diseases that vary temporally. Data regarding the sensitivity of MRSA surveillance by number of 
anatomic sites cultured are from a single cross-sectional study performed at two tertiary care 
facilities in Philadelphia, Pennsylvania: 1.The Hospital of the University of Pennsylvania (HUP) 
2.The Children’s Hospital of Philadelphia (CHOP).63 Surveillance was performed 
simultaneously on five anatomic sites by both medical staff and patient (or patient’s parents) 
immediately after: 1.Nares 2.Axillae 3.Throat 4.Groin 5.Perineum. The sensitivity of each 
culture was then determined comparing each individual, pair, or triplet of surveillance cultures to 
the gold standard of any positive culture from any anatomic site. The study population was 
comprised of 56 total participants: 49 adults and seven children. The investigators concluded that 
multiple surveillance sites were required to achieve sensitivity of ≥90%, although a single culture 
of the anterior nares in adults 84% sensitivity (95% CI: 71%- 92%).63 These data were utilized to 
model the variable sensitivity and cost (i.e., number of anatomic swabs collected) of MRSA 
testing strategies. These data were collected from a single city over a relatively short period of 
time, and they may not be generalizable. Computational modeling allows investigators to 
determine the economic and epidemiologic impact of variable MRSA prevalence utilizing point 
prevalence estimates from multiple cross sectional studies as upper and lower bounds of 
sensitivity analyses. 
Previous studies have evaluated the economic value of MRSA surveillance strategies and 
isolation protocols in adult inpatients, the incremental benefit of adding decolonization to an 
infection control program that already includes surveillance and isolation of positive patients, 
and the impact of PCR testing on MRSA bacteremia mortality rates.64-66 Each of these 
investigators came to the conclusion that MRSA surveillance and accompanying isolation or 
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decolonization was a cost-effective strategy. However, in a model developed by Murthy and 
colleagues utilizing clinical data from a Swiss teaching hospital that evaluated the economic 
value of universal PCR concluded that surveillance was not a cost-effective strategy because of 
their local epidemiological circumstances.67  This study assumed a very low baseline probability 
of MRSA infection of 0.0612 that may have contributed to the study’s conclusions.67 Moreover, 
clinical studies conducted in different healthcare facilities have utilized different MRSA tests as 
a part of their respective universal surveillance programs. Some investigators have used rapid 
PCR, others have utilized batched PCR protocols, and the remaining studies have implemented 
culture-based surveillance either with or without broth enrichment. Further analyses are needed 
to delineate the impact of local epidemiological circumstances and test characteristics on the 
ultimate economic value of MRSA surveillance strategies. 
A joint statement issued by the Society for Healthcare Epidemiology of America 
(SHEA), the Association for Professionals in Infection Control and Epidemiology (ACIP), the 
Pediatric Infectious Disease Society (PIDS), the Infectious Disease Society of America (IDSA), 
the Council of State and Territorial Epidemiologists (CSTE), the Association of State and 
Territorial Health Officials (ASTHO), and the CDC called for the elimination of healthcare 
associated infections.68-69 These groups defined the elimination of nosocomial infections as, “the 
maximal reduction of the incidence of infection caused by a specific agent in a defined 
geographical area as a result of deliberate efforts; continued measures to prevent reestablishment 
of transmission are required.”68-69 A four pillared strategy was proposed including: 1. Evidence-
based prevention efforts 2. Alignment of incentives 3. Innovative research 4. Data for action and 
responding to emerging diseases. The statement created a broad framework of infection 
prevention strategies and highlighted the importance of eliminating the nosocomial infections.  
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Each of the nosocomial infection prevention strategies described in the following chapters could 
be used by hospital administrators to move towards the CDC goal of eliminating nosocomial 
infections. The following chapters model the epidemiological and economic impact of changing 
surveillance test attributes, target populations, and intervention implementation strategies.  
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2.0  ALL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 
TESTS ARE NOT CREATED EQUAL: A COMPARATIVE ECONOMIC SIMULATION 
MODEL 
2.1 ABSTRACT 
Controversy remains over the impact of methicillin-resistant Staphylococcus aureus 
(MRSA) prevalence, net reproductive rate (R), anatomic sites tested (individually plated and 
plated together), turnaround time, and efficacy of contact isolation in preventing secondary cases 
on the ultimate economic value of MRSA testing. We developed a stochastic computer 
simulation model from the third party payor perspective to evaluate the differential impact of 
these parameters on the economic value of testing. MRSA prevalence, R, turnaround time, and 
contact isolation efficacy were major drivers of the cost effectiveness of surveillance. When R is 
1.0 and prevalence is 1% given a one day turnaround time the cost per case averted was $74,439 
with an incremental cost-effectiveness ratio (ICER) (i.e., dollars spent per quality-adjusted life 
year saved) of $11,110.  With two day turnaround, the cost per case averted increased to 
$156,802 and ICER increased to $29,207.  Similarly, as isolation efficacy increased from 25% to 
50% to 75%, cost per case averted decreased: 43,725 to 20,406 to 11,110 for one day turnaround. 
Decision makers should choose MRSA testing strategies with shorter turnaround time and work 
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to increase the efficacy of contact isolation protocols. Testing multiple anatomic sites whether on 
multiple plates or a single plate does not substantially improve the economic value.  
2.2 BACKGROUND 
Testing patients for methicillin-resistant Staphylococcus aureus (MRSA) may be a key 
intervention to control the spread of the pathogen, a substantial and continuing problem in 
healthcare facilities.16, 70 However, controversy remains over the number of anatomical sites that 
ought to be tested and the potential impact of turnaround time on the overall value of MRSA 
testing.30, 71-72 Testing protocols differ among healthcare facilities, and may affect the ultimate 
economic value of surveillance programs and other MRSA testing strategies.72-75 Therefore, not 
all MRSA testing strategies are equivalent. Understanding how such laboratory logistical 
questions may significantly impact the economic value of MRSA testing is important for making 
informed decisions. 
Ultimately, the optimal MRSA test and testing strategy is a balance of costs and potential 
benefits. Culturing more anatomic sites increases testing sensitivity, potentially identifying more 
asymptomatic carriers, but at the same time increases costs (e.g., increases the number of swabs 
and personnel time to collect and test the samples). Decreasing turnaround time reduces the time 
that carriers may transmit to others before being isolated, but also may bring additional costs 
(e.g., more costly rapid tests and information systems to transmit results back to the hospital 
floor). We developed a stochastic computer simulation model to evaluate the economic impact of 
varying different testing characteristics such as test turnaround time, sensitivity, specificity, cost 
per test, and the number anatomical sites swabbed.  Sensitivity analyses also explored the impact 
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of ranging MRSA prevalence, effectiveness of isolation in preventing secondary transmission, 
and net reproductive rate (R). 
2.3 METHODS 
2.3.1 Model Structure 
Figure 2.1 outlines the general structure of the stochastic simulation model developed 
using TreeAge Pro 2009 (TreeAge Software, Williamstown, MA) and Microsoft Excel 
(Microsoft Inc, Redmond, WA). Upon admission to an acute care hospital, each patient (median 
age: 40 years) has a probability of being MRSA colonized (MRSA prevalence) either undergoes 
or does not undergo MRSA screening of a single anatomical site (nares, throat, groin, perineum, 
or axillae), two anatomical sites (nares and throat, nares and groin, nares and perineum, nares 
and axillae), or three anatomical sites (nares, throat and groin; nares, throat and perineum; nares, 
throat and axillae). The number of sites tested affects the overall test cost, sensitivity, and 
specificity.  
Experiments varied the turnaround time to receive results and implement isolation for 
those with positive results between 1 and 2 days. A positive test (either true or false positive) 
resulted in a patient being placed on contact isolation, regardless of the patient's true colonization 
status. Contact isolation reduced the probability of the patient transmitting MRSA to non-
colonized patients. R determined the number of additional cases generated by each MRSA 
colonized patient that was not placed on contact precautions. Each of these additional cases 
could remain asymptomatically colonized or develop clinical infection resulting in any 
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combination of the following clinical sequelae (shown in Figure 2.2): abscess, bacteremia, 
cardiac surgery (prerequisite: endocarditis), cellulitis, endocarditis, line infection, pneumonia, 
osteomyelitis, septic shock (prerequisite: bacteremia), urinary tract infection (UTI), and wound 
infection (e.g., one MRSA colonized patient could develop only cellulitis while another could 
develop a line infection and bacteremia). The clinical sequelae determined the MRSA-
attributable mortality. Each clinical sequela required vancomycin for treatment of the following 
durations: endocarditis, 4-6 weeks; osteomyelitis, 6 weeks; UTI, 3-5 days; all others, 10-14 days. 
Clinical probabilities came from an extensive MEDLINE literature search which excluded case 
reports and case series and studies published prior to 2000, since prior standard of care may have 
differed from current practices. 
Table 2.1 outlines the diagnostic and therapeutic procedures, hospitalization costs, and 
quality adjusted life-year (QALY) decrements associated with each clinical sequela and its 
respective distribution. Patients with multiple sequalae were only assessed the cost of 
hospitalization for their most severe condition. A 3% discount rate converted costs to 2009 US 
dollars. The model assumed the third party payor perspective, and each simulation run consisted 
of 1,000 trials of 1,000 individuals or a total of 1,000,000 simulated patients traveling through 
the model. A one year time horizon was employed by the model. Comparable model methods are 
described in detail by Lee et al.64 
The primary model outcome measure was the incremental cost-effectiveness ratio 
(ICER), where cost is measured in dollars and effectiveness in quality-adjusted life-years 
(QALYs).   
ICER = (Cost with MRSA Testing - Cost without MRSA Testing) / (Effectiveness with 
MRSA Testing - Effectiveness without MRSA Testing).  
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Interventions with ICER values below $50,000/QALY are generally accepted to be cost-
effective.76 A secondary model outcome measure was the cost per case of MRSA averted, where 
a case is defined as either a symptomatic or asymptomatic secondary MRSA infection.  
 
Cost Per Case Averted = (Cost with MRSA Testing - Cost without MRSA Testing) / 
(Secondary Cases Without MRSA Testing – Secondary Cases with MRSA Testing).  
2.3.2 Sensitivity Analyses 
Sensitivity analyses systematically varied key model parameters such as MRSA 
prevalence (i.e. probability of colonization) from 0.1% to 25%12-13, 16-17, 20-22, 35, R from 0.25 to 
2.077, turnaround time from 1 to 2 days28, 74, 78, contact isolation efficacy from 25% to 75%48, 79-80 
(to represent variations in adherence to hand hygiene and contact isolation protocols), number of 
anatomic sites screened63, and the impact of screening multiple anatomic sites with a single agar 
plate (and single charge for surveillance).  
2.4 RESULTS 
The cost-effectiveness of surveillance was most impacted by local MRSA conditions 
(MRSA prevalence and R), turnaround time, and efficacy of isolation. Outcomes were less 
sensitive to anatomic sites tested, even when multiple cultures were analyzed on a single culture 
plate. As turnaround time increased, ICER value also increased, indicating that surveillance 
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results in a shorter time were more cost-effective. Additionally, as MRSA prevalence increased, 
testing became increasingly cost-effective.  
2.4.1 Local Prevalence and R 
As local MRSA conditions became more severe (i.e. higher local MRSA prevalence 
and/or R) surveillance became increasingly cost-effective.  Table 2.2 shows the ICER values 
decreased as both prevalence and R increased. This is true across all turnaround time, isolation 
efficacy, and sites cultured scenarios tested. Cost per case averted follows this same pattern, with 
decreasing cost per case averted as prevalence and/or R increased.  
2.4.2 Effects of Turnaround Time 
Turnaround time for culture results and the implementation of contact precautions had a 
considerable impact on the economic value of a surveillance program. As turnaround time 
increased, the economic value of surveillance decreased. When a single culture of the anterior 
nares was utilized, isolation had a 75% effectiveness, R=1.0, and prevalence was 1%, the ICER 
value was $11,110/QALY with a one day turnaround and increased to $29,207/QALY with a 
two day turnaround time. Similarly, for these same scenarios the cost per case averted was 
$74,439/case for a one day turnaround and more than doubled to $156,802/case for a two day 
turnaround.  
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2.4.3 Efficacy of Isolation 
The efficacy of isolation in preventing secondary cases of nosocomial MRSA had a 
considerable impact on both the ICER values and cost per case averted. With increasing isolation 
efficacy the economic value of surveillance increased. When R was 0.5, the prevalence of 
MRSA was 5% as isolation efficacy increased from 25% to 50% to 75% the ICER values for a 
single culture of the anterior nares with a two day turnaround time decreased as follows: 
$45,155/QALY to $17,703/QALY to $10,875/QALY. For these same scenarios the cost per case 
of MRSA averted decreased from $198,851/case to $103,498/case to $68,038 with increasing 
efficacy of isolation. 
2.4.4 Number of MRSA Colonizations and Infections Prevented 
The efficacy of isolation also impacted the number of secondary MRSA cases and 
infections. For scenarios where R was 0.5 and the prevalence of MRSA was 5%, without 
surveillance and isolation of those who tested positive there were a mean of 18.53 colonizations 
and 6.55 clinical infections. With low efficacy of isolation (i.e., 25%) 17.33 colonizations and 
6.07 clinical infections remained a decrease of only 6.52% and 7.35% for colonizations and 
clinical infections, respectively, from the baseline scenario without surveillance and isolation.  
As efficacy of contact isolation increased to 50%, there was a 14.31% and 14.11% decrease in 
MRSA colonizations and clinical infections, respectively, with 15.88 colonizations and 5.63 
clinical infections remaining. When efficacy of isolation was 75%, the greatest decline in MRSA 
cases was seen with a decrease of 20.08% of colonizations and 20.58% of infections. 
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2.4.5 Impact of Screening Multiple Anatomic Sites 
When each anatomic site is cultured on a separate agar plate there is not a clear 
correlation between number of anatomic sites cultured and the economic value of surveillance. 
When isolation efficacy was 75%, turnaround time was 2 days, MRSA prevalence was 5%, and 
R was 0.5, the ICER actually increased slightly with an increasing number of sites: testing the 
nares only, a pair of cultures of the nares and throat, and a triplet of cultures of the nares, throat, 
and axillae. For these scenarios ICER values increased from $10,875/QALY to $11,432/QALY 
to $11,649/QALY and the cost per case averted also increased from $68,038/case to 
$76,601/case to $82,249/case, respectively.  Economic value of surveillance decreased (i.e., had 
a higher ICER value) as number of anatomic sites cultured on unique plates increased.  
2.4.6 Plating Multiple Cultures on a Single Plate 
When multiple surveillance swabs are plated together and the patient is only charged for 
a single test ($50), surveillance of multiple anatomic sites became increasingly cost-effective. 
When isolation efficacy was 75%, turnaround time was 2 days, MRSA prevalence was 2.5%, and 
R was 1.0, the ICER decreased from $12,042/QALY for a culture only of the anterior nares to 
$10,383/QALY for a pair of cultures of the nares and throat to $8,907/QALY for a triplet culture 
of the nares, throat and axillae when cultured on a single agarose plate. The cost per case averted 
for these scenarios displayed a similar pattern, decreasing from $190,475/case to $183,701/case 
to $174,780/case for the nares only, nares and throat cultures, and nares, throat, and axillae 
scenarios, respectively. These scenarios display some stochasticity, given MRSA prevalence of 
25% and R of 0.5, the same three testing strategies’ ICERs are $3,556/QALY, $3,826/QALY, 
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and $3,595/QALY, respectively.  Each of these testing strategies is strongly cost-effective falling 
well below the $50,000/QALY threshold.  Cost per case averted for these scenarios ranges from 
$62,173/case to $66,749/case.   
2.5 DISCUSSION 
Our analyses demonstrate the paramount importance of test turnaround time and contact 
isolation effectiveness in determining the economic value of MRSA testing.  In other words, all 
MRSA testing and surveillance strategies are not the same, which may explain the varying 
economic value of surveillance found by previous clinical studies and economic models.55, 64, 70, 
72-75, 81-82 This suggests that both future clinical studies and infection control guidelines ought to 
clearly outline the MRSA test characteristics, protocols following positive test results, and 
adherence to contact isolation protocols. 
Olchanski and colleagues developed an Excel-based Monte Carlo simulation model that 
assessed the impact of test characteristics on the clinical and economic value of MRSA testing in 
U.S. hospitals.83 This model evaluated the impact of a variety of MRSA testing strategies both 
culture based and PCR. However, this study had a mean MRSA-attributable LOS of 9 days 
(range: 4-12 days) which is substantially longer than the MRSA-attributable LOS utilized in our 
analyses and a lower test cost utilized in sensitivity analyses of $5-$25. Both of these parameter 
estimates may impact the ultimate economic value of a MRSA testing strategies. Further, our 
analyses also evaluated the economic value of surveillance by anatomic site cultured which 
provides further insight to decision makers choosing a surveillance strategy to implement in their 
facility. 
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Our study may help guide future development of MRSA tests.  Aiming for rapid 
turnaround times may be more important than increased sensitivity afforded by either testing 
more anatomic sites or an inherent characteristic of the test itself.  Budgetary constraints often 
dictate how MRSA testing protocols are implemented. When considering a MRSA surveillance 
program, decision makers must decide which aspects of testing to prioritize. Increased sensitivity 
requires additional cultures, which our results suggest are not justified by the additional testing 
cost. Developers of MRSA tests should aim to minimize turnaround time, whether by 
polymerase chain reaction (PCR), enhanced broth enrichment, or by way of a novel approach. 
Computational models can help decision makers understand what the potential economic impact 
of enhancing different test characteristics may be. To increase the sensitivity of MRSA testing 
strategies, broth enrichment is often utilized. The longer that is sample is enriched, the higher the 
sensitivity, although this is a non-linear increase. Therefore, understanding the benefit that a less 
sensitive rapid test may have in terms of both epidemiologic and economic outcomes compared 
to a more sensitive test that requires 48 hours or more of enrichment is valuable information for 
test developers. 
Hospital decision makers can also utilize the results of our study. Infection control 
personnel can critically evaluate their testing and contact isolation protocols and use our model 
to benchmark the approximate economic value of MRSA testing in their respective facilities. 
Hospital administrators are able to evaluate their facility’s adherence to isolation protocols as a 
metric of the potential value of a MRSA surveillance program in their facility. The widespread 
implementation of rapid testing methods or the use of information systems that quickly 
communicate results to nurses who place patients in isolation may be necessary for a MRSA 
surveillance program to be cost-effective and minimize the cost per case averted. Poor adherence 
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to isolation protocols results in less economically favorable MRSA surveillance programs. To 
mitigate the impact of low adherence to isolation protocols healthcare facilities may need to 
implement increased staff education, additional signage reminding medical and non-medical 
staff and hospital visitors that a patient is on contact isolation, or other local solutions that will 
increase adherence to isolation protocols. 
2.5.1 Limitations 
Models are a decision making aid, and are not meant as a replacement of classic 
epidemiological studies. When considering the optimal MRSA testing strategy, hospital 
administrators ought to consider local epidemiology of MRSA, available laboratory resources, 
infection control practices, and costs. We aimed to be conservative in estimating the economic 
value of MRSA testing, including only the most common sequelae and costs. Other studies83 
have utilized longer estimates of MRSA-attributable LOS and the accompanying costs of MRSA 
infections that may lead to differences in estimates of the economic value of MRSA testing 
strategies.  
2.5.2 Conclusions 
Choosing a MRSA testing method is a complex balance of test attributes. Our results 
suggest that the higher costs of multiple surveillance sites are not justified by the incremental 
gains in test sensitivity, and in fact, the test turnaround times may be a larger driver of the 
economic value of a MRSA testing strategy.  Infection control guidelines that mandate MRSA 
surveillance need to be cognizant that not all MRSA testing programs are equally valuable. 
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Delaying the implementation of isolation protocols allows sufficient time for asymptomatic 
patients to transmit MRSA, substantially decreasing the economic value of testing. More 
widespread use of rapid MRSA testing methods that decrease the time that those individuals who 
are asymptomatically colonized remain in contact with those who are susceptible to MRSA 
acquisition, would likely increase the economic value of testing programs. Resources should be 
devoted to decreasing turnaround time to increase the economic value of MRSA testing and 
nosocomial infection rates. 
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2.6 FIGURES AND TABLES 
 
 
Figure 2.1: Model Structure 
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Figure 2.2: Clinical Infection Outcomes Subtree 
a QALY decrements persist for 2 weeks. 
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Table 2.1: Model Inputs 
Model Parameter Mean Value Range or 
Standard 
Deviation 
Distribution 
Type 
Source 
Costs (2010 US$)     
   Contact Isolation 6,500 4,290-8,710 Triangular 84 
   Excess Hospitalization 
      Abscess 3,877 534 Gamma 85 
      Bacteremia 8,250 416 Gamma 85 
      Cardiac Surgery 38,317 1,088 Gamma 85 
      Cellulitis 4,140 130 Gamma 85 
      Endocarditis 13,996 2,964 Gamma 85 
      Line Infection 11,717 3,277 Gamma 85 
      Osteomyelitis 8,694 963 Gamma 85 
      Pneumonia 13,498 463 Gamma 85 
      Septic Shock 13,772 4,344 Gamma 85 
      Urinary Tract Infection (UTI) 4,906 112 Gamma 85 
      Wound Infection 4,099 266 Gamma 85 
  Therapeutic and Diagnostic Procedures 
      Blood cultures, 2 sets   31 21-42 Triangular 86 
      Cardiac surgery   1,278 843-1,712 Triangular 85 
      Computerized tomography,  
      chest   
244 161-327 Triangular 85 
      Echocardiogram,  
      transesophageal   
169 11-226 Triangular 85 
      Echocardiogram, transthoracic   170 112-227 Triangular 85 
      Incision and drainage   334 220-447 Triangular 85 
      Magnetic resonance imaging,  
      extremity   
479 316-641 Triangular 85 
      Orthopedic hardware  
      replacement   
1,779 1,174-2,384 Triangular 85 
      Peripheral intravenous line  
      insertion   
151 99-202 Triangular 85 
      Peripherally inserted central   
      catheter insertion   
290 191-389 Triangular 87 
      Radiograph, extremity   30 20-40 Triangular 85 
      Surgical replacement of graft   1,299 857-1,741 Triangular 85 
      Ultrasound, Doppler   128 84-171 Triangular 85 
      Urinalysis   6 4-9 Triangular 85 
      Urine culture   58 44-73 Triangular 85 
      Wound culture   50 42-58 Triangular 88 
      Wound debridement 72 47-96 Triangular 85 
     
Test Characteristics Probability, %   
   Surveillance Sensitivity: Single Sites    
      Nares Only 84 71-92 Triangular 63 
      Throat Only 65 51-78 Triangular 63 
      Axillae Only 31 19-45 Triangular 63 
      Groin Only 38 25-52 Triangular 63 
      Perineum Only 40 27-54 Triangular 63 
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Table 2.1: Continued 
Test Characteristics Probability, %   
   Surveillance Sensitivity: Combinations of Sites 
      Nares and throat  91 80-97 Triangular 63 
      Nares and axillae  85 73-94 Triangular 63 
      Nares and groin  85 73-94 Triangular 63 
      Nares and perineum  87 76-95 Triangular 63 
      Nares, throat, and axillae  93 82-98 Triangular 63 
      Nares, throat, and groin  98 90-100 Triangular 63 
      Nares, throat, and perineum  95 85-99 Triangular 63 
     
   Surveillance Specificity 97.1 92.2-99.5 Triangular 78 
   Invasive Infection, Given  
  Colonization 
26.00 17.65 Beta 19-25, 89 
   Sequalae, Conditional on Invasive  Infection    
      Abscess 4.17 3.13-5.21 Triangular 20 
      Bacteremia 27.70 31.42 Beta 90-95 
      Cardiac Surgery 38.87 32.46 Beta 92, 96-99 
      Cellulitis 37.04 32.62 Beta 94, 99-100 
      Endocarditis 33.33 20.66 Beta 91, 101-102 
      Line Infection 32.56 15.99 Beta 61, 96-97, 103-107 
      Osteomyelitis 13.54 10.16-16.93 Triangular 104, 108 
      Pneumonia 38.15 30.83 Beta 61, 90, 102-105, 107-109 
      Septic Shock 22.70 10.05 Beta 96-97, 107, 110 
      Urinary Tract Infection (UTI) 9.39 4.64 Beta 61, 94, 104, 107-108 
      Wound Infection 27.45 14.76 Beta 61, 90, 103-105 
   Mortality, by Sequela     
      Bacteremia 29.38 -- -- 61, 90, 93-95, 98, 103-109, 111-
115 
      Cardiac Surgery 17.91 -- -- 116-118 
      Endocarditis 40.71 -- -- 61, 92, 96-97, 99, 101-105 
      Pneumonia 31.38 -- -- 90, 93-95, 102, 119-122 
      Septic Shock 60.77 -- -- 123 
     
Utilities  (Quality-Adjusted Life-Years (QALYs))a 
      Abscess 0.642 -- -- 124-125 
      Bacteremia 0.530 -- -- 124, 126 
      Cardiac Surgery 0.500 -- -- 124, 127 
      Cellulitis 0.642 -- -- 124-125 
      Endocarditis 0.530 -- -- 124, 126 
      Line Infection 0.642 -- -- 124-125 
      Osteomyelitis 0.530 -- -- 124, 126 
      Pneumonia 0.580 -- -- 124, 128 
      Septic Shock 0.530 -- -- 124, 126 
      Urinary Tract Infection (UTI) 0.730 -- -- 124, 128 
      Wound Infection 0.642 -- -- 125 
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Table 2.2:  Incremental Cost-Effectiveness Ratio (ICERs) (Cost per quality-adjusted life-
year saved) by varying surveillance site, turnaround time, MRSA prevalence and net 
reproductive rate (R) 
2 Day Turnaround Time 
 Net Reproductive Rate (R) 
Anatomical Site  0.25 0.5 1.0 1.5 
MRSA Prevalence 1% 
Single Swab: Nares 46,936 52,772 29,207 18,052 
Single Swab: Throat 163,343 120,991 34,853 24,235 
Two Swabs: Nares & Throat 51,832 31,984 41,342 25,921 
Three Swabs: Nares, Throat, & Axillae 339,547 44,964 34,065 19,561 
MRSA Prevalence 2.5% 
Single Swab: Nares 47,027 24,336 9,674 8,501 
Single Swab: Throat 36,563 23,244 14,355 9,782 
Two Swabs: Nares & Throat 33,734 24,293 10,826 8,522 
Three Swabs: Nares, Throat, & Axillae 34,431 24,372 15,124 9,035 
MRSA Prevalence 5% 
Single Swab: Nares 29,129 10,875 5,919 3,815 
Single Swab: Throat 26,542 18,496 6,413 5,275 
Two Swabs: Nares & Throat 23,022 11,432 5,889 3,766 
Three Swabs: Nares, Throat, & Axillae 16,465 11,649 7,070 5,132 
MRSA Prevalence 15% 
Single Swab: Nares 7,756 4,897 2,658 1,478 
Single Swab: Throat 10,378 5,529 3,024 1,699 
Two Swabs: Nares & Throats 9,279 5,889 2,541 1,622 
Three Swabs: Nares, Throat, & Axillae 12,281 5,831 2,791 1,844 
MRSA Prevalence 25% 
Single Swab: Nares 6,906 4,212 1,742 1,072 
Single Swab: Throat 7,874 4,620 1,887 1,587 
Two Swabs: Nares & Throat 7,512 4,037 1,885 1,177 
Three Swabs: Nares, Throat, & Axillae 8,613 4,631 1,918 1,258 
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Table 2.2:  Continued 
1 Day Turnaround Time 
 Net Reproductive Rate (R) 
Anatomical Site  0.25 0.5 1.0 1.5 
MRSA Prevalence 1% 
Single Swab: Nares 50,665 26,976 11,110 9,071 
Single Swab: Throat 189,865 110,343 23,915 19,646 
Two Swabs: Nares & Throat 2,145,655 62,090 34,509 25,007 
Three Swabs: Nares, Throat, & Axillae 71,252 53,316 29,678 16,025 
MRSA Prevalence 2.5% 
Single Swab: Nares 19,165 13,326 6,175 3,586 
Single Swab: Throat 48,261 19,142 11,383 9,152 
Two Swabs: Nares & Throat 43,793 44,788 11,434 8,069 
Three Swabs: Nares, Throat, & Axillae 42,818 22,213 13,365 8,555 
MRSA Prevalence 5% 
Single Swab: Nares 12,959 6,138 2,707 1,821 
Single Swab: Throat 23,163 11,816 5,612 4,057 
Two Swabs: Nares & Throat 23,761 13,554 6,023 4,400 
Three Swabs: Nares, Throat, & Axillae 39,172 14,616 6,665 4,227 
MRSA Prevalence 15% 
Single Swab: Nares 5,352 2,502 1,152 632 
Single Swab: Throat 11,559 5,522 2,729 1,589 
Two Swabs: Nares & Throats 10,846 5,173 2,347 1,661 
Three Swabs: Nares, Throat, & Axillae 11,029 6,211 2,782 1,791 
MRSA Prevalence 25% 
Single Swab: Nares 4,194 1,737 742 423 
Single Swab: Throat 6,743 4,009 1,695 1,223 
Two Swabs: Nares & Throat 8,023 3,524 1,903 1,153 
Three Swabs: Nares, Throat, & Axillae 9,117 4,449 1,951 1,258 
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3.0  SHOULD NEWBORNS IN THE NEONATAL INTENSIVE CARE UNIT BE 
SCREENED FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS 
(MRSA)? 
3.1 ABSTRACT 
Methicillin-resistant Staphylococcus aureus (MRSA) is a cause of substantial morbidity 
and mortality in the neonatal intensive care unit (NICU). Active surveillance in the NICU (i.e., 
testing all neonates to determine MRSA colonization status and increasing infection control 
precautions to prevent spread of the pathogen) has been suggested as an outbreak prevention 
measure and has been previously used in outbreak control. We developed a Markov simulation 
model that depicted the decision of whether or not to implement weekly agar-based surveillance 
in the NICU in a United States hospital from the third party payer perspective. Weekly 
surveillance for MRSA in the NICU was cost-effective across all scenarios we tested, with 
incremental cost-effectiveness ratio values <$10,000/QALY. As the annual MRSA incidence 
increased, the number of neonates needed to screen to prevent a single case of MRSA (i.e., 
colonization or infection) decreased. When R=0.5, annual MRSA incidence was 2.5%, and there 
was 50% isolation efficacy in preventing secondary cases of MRSA, 102 neonates would need to 
have weekly surveillance cultures to prevent a single MRSA case. Increasing contact isolation 
efficacy to 75% for the same scenario would decrease the NNS to 66 neonates. Our study 
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suggests that hospitals with moderate to high adherence to increased contact precautions 
protocols could benefit from the implementation of active surveillance. Hospitals ought to 
consider adding active surveillance for MRSA to a suite of NICU infection control precautions 
as an effective measure for preventing excess morbidity and mortality. 
3.2 INTRODUCTION 
Methicillin-resistant Staphylococcus aureus (MRSA) is a cause of substantial morbidity 
and mortality in the neonatal intensive care unit (NICU), not only in the United States, but also 
worldwide.5, 41-42, 129-136  Neonates in the NICU may have limited ability to mount a full immune 
responses, making them particularly vulnerable to MRSA infections.137 Active surveillance in 
the NICU (i.e., testing all neonates to determine MRSA colonization status and increasing 
infection control precautions to prevent spread of the pathogen) has been suggested as an 
outbreak prevention measure and has been previously used in outbreak control.41-42, 131, 134, 136  
However, systematic MRSA testing of all neonates in the NICU can be a costly undertaking, and 
hospitals may have limited financial resources. Therefore, understanding the economic 
implications of infection control protocols before implementation is valuable for hospital 
decision makers. We constructed an economic simulation model to evaluate the potential 
economic value of active MRSA surveillance in the NICU. 
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3.3 METHODS 
We developed a Markov simulation model that depicted the decision of whether or not to 
implement weekly agar-based surveillance in the NICU in a United States hospital from the third 
party payer perspective using TreeAge Pro 2009 (Williamstown, MA) and Microsoft Excel 
(Redmond, WA). Each newborn that entered the NICU had a probability of contracting MRSA 
based on the local hospital prevalence. All newborns received a single anterior nares culture 
upon admission to the NICU. Additionally, each received an additional weekly culture for the 
duration of stay. Length of stay (LOS) was pulled from a distribution of MRSA positive neonates 
or a distribution of Methicillin-susceptible Staphylococcus aureus (MSSA) neonates from a 
longitudinal NICU surveillance study.5 Sensitivity analyses also varied this increased LOS with 
MRSA infection. 
Each culture returned a positive or negative result based on the sensitivity and specificity 
of the surveillance test and a newborn’s true colonization status. All newborns with a positive 
surveillance culture, whether a true positive or false positive, were placed under increased 
contact precautions for the remainder of that week. The cost of increased contact precautions was 
a function of the number of nurse contacts per day, the costs of gloves and gowns, and the nurse 
time required to don this personal protective equipment. Newborns with a negative culture, 
whether a true negative or false negative, were not placed under increased contact precautions; 
those newborns with a false negative surveillance result were able to transmit MRSA to other 
newborns in the NICU. Neonates who were colonized and did not have a surveillance culture 
were not placed under increased contact precautions and transmitted the net reproductive rate (R) 
cases to other neonates. Increased contact precautions attenuated, but did not eliminate, these 
secondary cases proportional to the efficacy of the contact precautions. 
 37 
 
Figure 3.1a outlines the structure of the model. There were 3 mutually exclusive Markov 
states:  
1. No MRSA colonization or infection  
2. MRSA colonized or infected  
3. No longer in the NICU (due to neonatal death or discharge from the NICU).  
Each neonate occupied a state for the duration of a cycle (1 week) and then had a probability of 
transitioning to the other Markov states.  All probabilities are outlined on Table 3.1. MRSA 
colonized neonates had a probability of developing a clinical infection. 
All neonates with clinical MRSA infections were assumed to be placed under increased 
contact precautions, regardless of surveillance culture status. Figure 3.1b outlines the general 
flow of neonates in the model and Figure 3.1c outlines the clinical MRSA infection outcomes. In 
our study, clinical MRSA infections were defined as bacteremia, conjunctivitis, or skin and soft 
tissue infections (SSTIs). Each infection required the therapeutic and diagnostic procedures 
outlined on Table 3.1. Additionally, each infected neonate was treated with intravenous 
vancomycin. Dosing of vancomycin was based on a neonate’s weight; a 10 day course of 
treatment was required for SSTIs and a 14 day course of treatment was the treatment for 
bacteremia. Conjunctivitis was treated with combination trimethoprim/polymyxin eye drops for 
10 days. To convert past and future costs to 2010 dollars, we utilized a 3% discount rate. 
 
Neonates who were colonized with MRSA and not placed under increased contact 
precautions (i.e. the neonates under the no surveillance branch of the model or those neonates 
with false negative surveillance cultures) were able to transmit MRSA to other neonates in the 
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NICU equal to R.  Since R for MRSA is not well described in the literature, we systematically 
varied this parameter. When R=0.5, for every two MRSA cases in the NICU there was one 
secondary case in the NICU. Similarly, when R=1.5, for each primary case in the NICU, 1.5 
secondary cases were produced. Neonates who were placed under increased contact precautions 
had an R value that was attenuated by the efficacy of isolation. However, these neonates were 
assumed to still transmit a fraction of the R value due to imperfect adherence to isolation 
protocols.  
3.3.1 Sensitivity Analyses 
Sensitivity analyses systemically varied key model inputs that are known to vary 
geographically and temporally. We performed sensitivity analyses for the following model inputs 
and respective ranges: annual MRSA incidence (1% to 15%)39, 62, 129, 138-139, R (0.5-1.5)77, 
efficacy of increased contact precautions in preventing secondary MRSA transmission in the 
NICU (25-75)48, and relative increase in LOS for MRSA infection (10% to 33%)42, 138-139. 
Additionally, probabilistic sensitivity analyses simultaneously varied all parameters over their 
respective ranges on Table 3.1. 
3.3.2 Outcomes Measures 
 The cost and number of neonates needed to screen to prevent one case (i.e., MRSA 
colonization or clinical infection) was the primary outcome assessed in the model. A secondary 
outcome was the incremental cost-effectiveness ratio (ICER). The ICER calculated the cost per 
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quality-adjusted life year (QALY) gained with surveillance. The following formula calculated 
the ICER for each simulation:  
ICER= 
(Cost with MRSA Surveillance – Cost without MRSA Surveillance) 
(Effectiveness with MRSA Surveillance – Effectiveness without MRSA Surveillance) 
 
ICER values ≤$50,000/QALY are generally regarded as cost -effective.76 When 
surveillance was both less costly and provided better health outcomes (i.e., a higher effectiveness 
value) than no surveillance, it was regarded as the dominant strategy.  
3.4 RESULTS 
3.4.1 General Results 
 Weekly surveillance for MRSA in the NICU was cost-effective across a wide range of 
testing strategies and local MRSA conditions. With increasing efficacy of isolation in preventing 
secondary MRSA cases in the NICU, an increasing economic value of MRSA surveillance in the 
NICU was observed. Across all scenarios we tested weekly MRSA surveillance of neonates in 
the NICU was strongly cost-effective, with ICER values <$10,000/QALY. As excess MRSA 
attributable stay increased, the economic value of surveillance also increased. 
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3.4.2 Number Needed to Screen to Prevent One MRSA Case 
The primary model outcomes measure was the number of neonates needed to screen on a 
weekly basis for the duration of their stay to prevent a single MRSA case in the NICU. We 
estimated the number needed to screen (NNS) for varying annual MRSA incidence and contact 
isolation efficacy. As the annual MRSA incidence increased, the NNS decreased. When R=0.5, 
annual MRSA incidence was 2.5%, and there was 50% isolation efficacy in preventing 
secondary cases of MRSA, 102 neonates would need to have weekly surveillance cultures to 
prevent a single MRSA case. Increasing contact isolation efficacy to 75% for the same scenario 
would decrease the NNS to 66 neonates. Similarly, if a hospital had a 5% annual MRSA 
incidence rate, R=0.5, and 75% isolation efficacy, then only 33 neonates would need to be 
screened to prevent a MRSA case. Figure 3.2 outlines how NNS screen to prevent one infection 
(Figure 3.2a) and one case of MRSA (Figure 3.2b) varied by annual MRSA incidence rates and 
contact isolation efficacies when R=0.5.  
3.4.3 Cost Per MRSA Case Averted 
We also calculated the cost per MRSA case averted with the implementation of 
surveillance and increased contact precautions in the NICU for varying annual MRSA incidence, 
R, and contact isolation efficacy.  When annual MRSA incidence was low (1%) and the efficacy 
of contact isolation was also relatively low (25%) then the cost per case averted was relatively 
high, costing $92,175/MRSA case averted. As the efficacy of contact isolation increased to 50%, 
the associated cost per case averted substantially decreased to $46,942/ MRSA case. Further, as 
the efficacy of contact isolation increased to 75% the cost per case averted decreased to $30,264. 
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This trend was consistent across annual MRSA incidence rates, as can be seen on Figure 3.3a 
which outlines the cost per MRSA infection averted and 3.3b outlining the cost per MRSA case 
(infection or colonization) averted for varying MRSA incidence and contact isolation efficacy, 
when R=0.5. Lower costs per case averted are a better economic value. 
3.4.4 ICER Values 
For all scenarios tested the ICER values were <$10,000, representing a cost-effective 
intervention. Similar to the number needed to treat analyses and cost per case averted, the 
economic value of surveillance increased as the annual MRSA incidence increased. Additionally, 
as the net reproductive rate increased, the ICER values also decreased, signifying an increased 
economic value. As long as the efficacy of isolation in preventing secondary MRSA cases in the 
NICU was ≥50%, then th e ICER values were <$5,000/QALY across all tested annual MRSA 
incidence rates.  
3.5 CONCLUSIONS  
Our study suggests that active surveillance in the NICU would be an economically 
valuable intervention across a wide range of scenarios. Debate remains about the economic and 
health value of MRSA surveillance. Our study suggests that hospitals with moderate to high 
adherence to increased contact precautions protocols could benefit from the implementation of 
active surveillance. Vertical transmission of S. aureus is relative rare, which suggests that the 
majority of MRSA cases in the NICU are the result of preventable instances of horizontal 
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transmission.140 Hospitals ought to consider adding active surveillance for MRSA to a suite of 
NICU infection control precautions as an effective measure for preventing excess morbidity and 
mortality. Hospitals with a high annual MRSA incidence can prevent a substantial number of 
nosocomial infections with active surveillance and isolation. Those facilities with a lower annual 
MRSA incidence and moderate adherence to increased contact precautions (≥50% efficacy) can 
also benefit by preventing nosocomial MRSA cases. 
Hospitals with large NICUs and moderate to high adherence (≥50% efficacy) to utilizing 
contact precautions should implement weekly surveillance in their facilities to prevent neonatal 
morbidity and mortality. Outbreaks of MRSA in the NICU could be prevented if routine 
surveillance were implemented to identify and isolate asymptomatic carriers. Monoclonal 
outbreaks, such as the outbreak that occurred at University of Bonn Hospital, Bonn, Germany 
from November 2005 to January 2006, could be prevented with routine surveillance and 
heightened infection control practices.141 In this hospital, before the outbreak routine MRSA 
surveillance was not utilized by infection control personnel. However, serial surveillance of the 
nares, throat, axilla, anus, groin, and stool was successfully utilized as an infection control 
strategy that was able to halt the outbreak when neonates who tested positive were decolonized. 
Further, these investigators advocate the utilization of routine screening and decolonization 
and/or exclusion of healthcare workers in the NICU who may be persistent carriers of MRSA.  
Routine screening strategies have been key components of outbreak containment programs. 
Hospitals should strongly consider implementing NICU screening as a routine infection 
prevention program. 
In addition to the University of Bonn Hospital outbreak, numerous outbreaks of MRSA in 
the NICU have been reported globally. Often these outbreaks have significant morbidity and 
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mortality that may have been prevented with increased contact precautions, especially among 
asymptomatically colonized neonates.5, 41-42, 129-130, 133-134, 136, 142 Asymptomatic neonates can be 
colonized with S. aureus on their skin, umbilicus, nares, and perineum. Systematic 
decolonization of all neonates in the NICU as an outbreak control measure has led to mupirocin 
resistance.38 Aggressive contact isolation protocols can also interrupt transmission of MRSA in 
the NICU without applying the selective pressure that has been documented to induce mupirocin 
resistance in the NICU. Hospital infection control personnel ought to consider implementing 
weekly NICU surveillance as a MRSA prevention measure. 
3.5.1 Limitations 
Our model evaluated routine active surveillance and increased contact precautions for 
positive neonates. We did not evaluate the potential impact of decolonization on surveillance 
positive neonates. Our study focused on surveillance of only the newborns, not the medical staff 
in the NICU. Finally, we evaluated only the most common MRSA sequelae in neonates (SSTIs, 
conjunctivitis, and bacteremia) and did not evaluate more rare MRSA infections. 
3.5.2 Conclusions and Future Directions 
Our results showed that performing MRSA surveillance in the NICU is a cost-effective 
strategy for a wide range of local MRSA conditions.  Our model provides benchmarks of local 
epidemiological conditions that assist physicians, hospital administrators, and policy makers 
make decisions about whether to implement surveillance at their hospitals.  Despite the upfront 
costs of performing MRSA surveillance, timely implementation of increased contact precautions 
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may prevent a significant number of MRSA cases among neonates.  Systematic mupirocin 
application for all neonates during outbreaks has induced mupirocin resistances, limiting future 
treatment options.  With an increasing number of state and local governments requiring 
surveillance of all patients in high risk units or intensive care units, understanding the potential 
economic value and preventable disease burden will allow for informed public health policy.  
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3.6 FIGURES AND TABLES 
 
Figure 3.1a: Markov States 
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Figure 3.1b: Model Structure 
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Figure 3.1c: MRSA Infection Outcomes 
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Figure 3.2: Number of neonates needed to screen to prevent one MRSA infection (a.) and one 
MRSA case (b.) for varying annual MRSA incidence and isolation efficacy, given R=0.5 
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 Figure 3.3: Cost per MRSA infection (a.) and MRSA case (b.) averted for varying annual MRSA incidence  
and isolation efficacy, given R=0.5 
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Table 3.1: Model Parameters and Sources 
Description Mean Range Distribution Source 
  Lower 
Limit 
Upper 
Limit 
  
Costs (2010 USD) 
Increased Contact Precautions      
Per Patient Contact      
Gloves $0.09 -- -- -- 143 
Gowns $0.92 -- -- -- 143 
Hand Hygiene $0.12 -- -- -- 143 
Nurse Time to Don Contact 
Precautions, Minutes 
1.0 -- -- -- 143 
Hourly Nurse Wage $30.65 $21.14 $45.05 Triangular 144 
Patient Contacts Per Day 78 -- -- -- 145 
Procedures      
Bacteremia      
Blood Culture  $14.79 -- -- -- 33 
Complete Blood Count,  
            Automated 
$9.27 -- -- -- 33 
Conjunctivitis      
Bacterial Culture $12.34 -- -- -- 33 
Blood Culture with White  
Blood Cell Count 
$4.93 -- -- -- 33 
 Nasal Smear $6.80 -- -- -- 33 
Skin & Soft Tissue Infection (SSTI)      
Bacterial Culture $12.34 -- -- -- 33 
Blood Culture  $14.79 -- -- -- 33 
Incision and Drainage $487.95 -- -- -- 146 
Hospitalization      
Bacteremia $5,750 $5,042 $6,457 Gamma 146 
Conjunctivitis $3,191 $2,915 $3,468 Gamma 146 
Skin & Soft Tissue Infection (SSTI) $3,586 $3,434 $3,740 Gamma 146 
Mortality, All Causes $7,129 $5,347 $9,296 Triangular 147 
      
Antibiotics      
Trimethoprim/polymyxin  
eye drops (10mL) 
$28.01 $3.52 $81.55 Gamma 148 
Vancomycin, (10 mg/kg) $0.84 -- -- -- 148 
MRSA Surveillance      
Agar Surveillance $12.34 -- -- -- 33 
Polymerase Chain Reaction  
(PCR) 
$50.27 -- -- -- 33 
Nasal Swab $2.19 -- -- -- 33 
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* Standard Deviation 
†Given a clinical MRSA infection. 
‡Decrement assumed to persist one week. 
 
Table 3.1 continued      
Probabilities (%) 
Clinical MRSA Infection† 16 2* -- Beta 5, 42, 62, 134, 136, 139 
Bacteremia† 46 21* -- Beta 5, 42, 62, 134, 136, 138-
139, 149 
Conjunctivitis† 40 13* -- Beta 5, 42, 136 
 
            Soft tissue infection† 31 16* -- Beta 5, 42, 62, 134, 138-139, 
149 
MRSA Mortality† 19 13* -- Beta 149-152 
Weekly Mortality, All Causes      
            Neonates <28 weeks old 0.001115    153 
            Neonates ≥28 weeks old to  
            1 year old 
0.0000463    153 
Effectiveness, Quality-adjusted Life Years (QALYS) 
MRSA Infection‡ 0.642 0.24* -- Beta  
Durations, Days 
Length of Stay, With MRSA  64 35 109 Triangular 138 
Length of Stay, With MSSA 64 40 113 Triangular 138 
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4.0  THE ECONOMIC VALUE OF DISPENSING HOME-BASED PREOPERATIVE 
CHLORHEXIDINE BATHING CLOTHS TO PREVENT SURGICAL SITE 
INFECTIONS 
4.1 ABSTRACT 
To estimate the economic value of dispensing preoperative home-based chlorhexidine 
bathing cloth kits to orthopedic patients to prevent surgical site infections (SSIs), a stochastic 
decision analysis computer simulation model was developed from the hospital’s perspective 
depicting the decision of whether to dispense the kits preoperatively to orthopedic patients. We 
varied patient age, kit cost, SSI attributable excess length of stay, cost per bed day, patient 
compliance with the regimen, and cloth antimicrobial efficacy to determine which variables were 
the most significant drivers to the model’s outcomes. When all other variables remained at 
baseline and cloth efficacy ≥50%, patient compliance only had to be half of baseline (baseline 
mean: 15.3%, range 8.23-20.0%) for the chlorhexidine cloth strategy to be less costly and 
provide better health outcomes. When cloth efficacy fell to 10%, 1.5 times the baseline bathing 
compliance, the preoperative bath was also less costly and had better health outcomes. Our study 
favors the routine distribution of bathing kits. Even with low patient compliance and cloth 
efficacy values, distribution of bathing kits is an economically beneficial strategy for the 
prevention of SSIs. 
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4.2 INTRODUCTION 
Surgical site infections (SSIs) are a substantial problem in the United States. Of 46 
million surgeries performed annually, at least 1 in every 100 procedures is complicated by a SSI 
during the hospital stay.154 These infections are often associated with higher morbidity and 
mortality rates as well as increased lengths of stay. In 2002, there were approximately 1.7 million 
SSI cases, resulting in 99,000 deaths.155  The economic burden associated with these preventable 
morbidity and mortality rates is high, and a reduction in these values would be advantageous for 
healthcare facilities. 155-156  It is increasingly important that hospitals adopt preventive measures 
to increase the safety of their patients and reduce the high costs associated with these infections. 
Antiseptic bathing is one of the preoperative procedures recommended by the Centers for 
Disease Control and Prevention (CDC).157  Previous studies have shown that screening surgical 
patients for Staphylococcus aureus and selectively decolonizing those who test positive with a 
regimen including chlorhexidine baths is a cost-effective strategy.55-56 However, it remains 
unclear whether to routinely provide preoperative antiseptic bathing to all patients.  Low patient 
compliance rates coupled with varying antimicrobial efficacy reported in recent studies have 
limited adoption of this prevention technique [written personal communication with Aaron 
Johnson, MD on 05/10].158-161  
Our study focuses on the use of home-based patient applied chlorhexidine cloths because 
recent studies have shown them to be the optimal antiseptic agent for the preoperative bathing of 
orthopedic patients.160-161 Unlike other available antiseptic agents (i.e., alcohol and povidone-
iodine), chlorhexidine is relatively odorless and colorless, which results in higher observed 
compliance values. It is also inflammable, making it safer for use in the operating room, and it 
exhibits greater antibacterial power.16, 54, 80, 157, 162  Preoperative chlorhexidine rinse is available 
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both as a liquid soap as well as a saturated polyester cloth, with recent studies noting increased 
use of the polyester cloth over the liquid soap. Despite past reviews, which have deemed 
chlorhexidine bathing an unnecessary preoperative procedure, the results from recent clinical 
trials have been favorable [written personal communication with Aaron Johnson, MD on 
05/10].158-161 
Previous epidemiological studies evaluated the impact of distributing preoperative 
bathing kits in patients undergoing either knee or hip arthroplasty. This prospective study 
distributed preoperative bathing kits to 1,054 patients undergoing hip arthroplasty at Sinai 
Hospital of Baltimore from January 1, 2007 through December 31, 2008.160 These patients had a 
mean age of 58 years old (range: 16-89). Analyses were stratified by both risk level of the 
surgery (low, medium, and high risk) and surgeon (1-4). Baseline incidence of SSIs in this 
facility was 0.4% for low risk, 2.4% for medium risk, and 5.2% for high risk patients. Among the 
4 surgeons at Sinai Hospital of Baltimore, the baseline incidence stratified by surgeon varied 
from 0.2-4.8%. Among those who were compliant with home-based preoperative bathing there 
were no incident surgical site infections. These investigators also performed a study distributing 
the home-based bathing kits to preoperative knee arthroplasty patients at the same hospital.161 
There were 847 patients in the study with a mean patient age 63 years old (range 20-90 years 
old) included in the study. Among the 136 patients who were compliant in applying the 
preoperative bathing, there were no surgical site infections compared to 21 infections among the 
711 noncompliant individuals (3.0%). These studies both provided proof-of-concept data for the 
new non-woven preoperative bathing kits. However, they may have been underpowered given 
the relatively small sample of patients who chose to participate in the bathing program. In the 
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absence of better powered trials computational modeling can aid in delineating the potential 
epidemiologic and economic value of implementing preoperative home-based bathing. 
We designed a computer simulation model to determine the economic value from the 
perspective of the hospital of preoperative chlorhexidine bathing for orthopedic patients with 
polyester cloths. A variety of sensitivity analyses evaluated how varying patient compliance, 
patient age, chlorhexidine cloth efficacy (i.e., the accompanying decrease in probability of post-
operative surgical site infection with preoperative home-based bathing), excess length of stay 
attributable to SSI and costs influence the cost-effectiveness of the bathing strategy. 
4.3 METHODS 
Using TreeAge Pro 2009 (TreeAge Software Inc., Williamstown, MA), we developed a 
stochastic decision analytic computer simulation model depicting the decision of whether or not 
to distribute a chlorhexidine cloth kit to patients for home-based preoperative bathing (Figure 
4.1) in addition to standard in-hospital preoperative preparation. The model evaluated the effects 
of the distribution of preoperative chlorhexidine bathing kits for the prevention of SSI for 
patients undergoing orthopedic (hip and knee) surgery. Preoperative bathing refers to the 
application of the chlorhexidine cloths the evening before and the morning of the surgical 
procedure. Each kit contains twelve cloths; six cloths each for two preoperative baths that 
include the disinfection of a patient’s head, abdomen, arms, legs, back, and surgical site.160-161 In-
hospital preoperative procedures included preoperative antibiotic prophylaxis with infusion 
beginning 60 minutes prior to incision of either 1-2g intravenous cefazolin or 1.5g intravenous 
cefuroxime or 1g intravenous vancomycin. Additionally, surgical site preparation was with a 
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combination iodine poyacrylaex/alcohol preparation (DuraPrep® solution, 3M: St. Paul, 
Minnesota) and were standardized in both study populations.160-161 Postoperative procedures 
were also standardized among both the intervention and no intervention groups and have been 
described in detail in previous studies.160-161 
The model assumed the hospital perspective (i.e. the costs and health benefits 
experienced by the hospital) and simulated the possible cost-effectiveness of chlorhexidine cloth 
use under a range of conditions (varying patient age, cloth cost, cost per bed day, SSI attributable 
length of stay, patient compliance, and cloth antimicrobial efficacy). The hospital perspective 
includes only the inpatient costs associated with a surgical site infection including excess length 
of stay, antibiotics, isolation expenses, and physician and nurse time. Lost wages, travel 
expenses, and outpatient treatments are not included for analyses from the hospital perspective.11 
Outcomes were dependent upon the increased length of stay for patients who acquired an SSI 
and included only costs associated with this increase to provide an appropriate monetary 
valuation of the cost of SSIs.154 A patient’s risk of infection after surgery was dependent on SSI 
risk, cloth efficacy, and compliance data compiled from two similar studies [written personal 
communication with Aaron Johnson, MD on 05/10].160-161 
Each simulation run sent 1,000 orthopedic patients through the model 1,000 times for a 
total of 1,000,000 trials. Each patient was 63 years of age and healthy when entering the model, 
the median age of an individual undergoing orthopedic surgery. As each patient traveled through 
the model, he/she had the chance of accumulating costs and quality-adjusted life-years (QALYs) 
associated with the path he/she traveled. A healthy individual age 0-17 accrues 1 QALY per 
year. Individuals ages 18-64 can accrue a maximum of 0.92 QALYs during a healthy year, while 
those ≥65 years old accrue 0.84 QALYs during a healthy year. 128 After all of the patients ran 
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through the model, the costs and QALY values of the 1,000,000 trials were combined, and an 
average was computed for the simulation. 
For each simulation run, an incremental cost-effectiveness ratio (ICER) was used to 
calculate the added cost of maintaining a quality-adjusted life-year. The following equation 
calculates the ICER of employing chlorhexidine cloths as a preoperative technique to prevent 
SSIs: 
ICER= (CostChlorhexidine Cloth – CostNo Cloth)/ 
(Effectivness Chlorhexidine Cloth – EffectivenessNo Cloth) 
 
ICER values below $50,000/QALY were considered relatively cost-effective, and those 
above the threshold were not considered cost-effective.163  When the preoperative chlorhexidine 
cloth intervention is both less costly and provides better health outcomes than that of no 
intervention, it is known as the dominant strategy, i.e. there is no cost or health effect 
disadvantage in implementation. Likewise, when the chlorhexidine cloths are more costly and 
less effective than that of no cloth application, it is considered to be the dominated approach and 
implementation is discouraged. 
Table 4.1 lists the costs, probabilities, time intervals, and effectiveness values used as 
inputs for our preoperative chlorhexidine bath model as well as corresponding distributions and 
data sources. All input parameters assume triangular distributions, except the cost of the 
chlorhexidine cloths used for bathing, which assumes a gamma distribution. Triangular 
distributions are used when there is limited existing data, such as skewed confidence intervals 
with an upper and lower bound and resemble the shape of a triangle. Gamma distributions are 
used to account for variables with skewed distributions, such as costs.164 Using ICD-9 code 
 58 
81.54 for total knee replacement, hospital costs were extracted from the healthcare utilization 
project’s (HCUP) national inpatient survey; the cost per bed day was $4,771.146 Average 
wholesale cost of the chlorhexidine cloths was systematically determined using various online 
sources from which a mean and standard deviation were calculated. A 3% discount rate 
converted all costs into 2010 U.S. dollars.165 
Our model measured the effectiveness of a chlorhexidine cloth in quality-adjusted life-
years (QALY). Each medical condition caused a QALY decrement, which endured only for the 
duration of the ailment. Most patients undergoing an orthopedic procedure have an age-adjusted 
baseline QALY value of 0.84 as a result of older age. After the procedure, patients with SSI have 
a QALY value of 0.756, accounting for the decreased quality of life for the duration of a surgical 
site infection. Since all patients traveling through the model undergo the same surgical 
procedure, the associated QALY decrement value for orthopedic surgical patients was null and 
would not have affected the model’s outcomes.124, 128  SSIs have a mean duration of 9.5 days, so 
QALY values represented this fraction of the whole year. The time horizon, or period of time 
included in each simulation, was one year.   
In the model, the following variable definitions were utilized to describe the 
chlorhexidine cloth intervention. Patient compliance was defined as a patient’s probability of 
applying the preoperative baths are directed by their physician. Only patients who were 
compliant with the intervention preoperatively had a reduced risk of post-operative surgical site 
infection. Cloth efficacy was defined as the reduction is relative risk of post-operative surgical 
site infection compared to no intervention, (i.e., if cloth efficacy was 25%, then a patient had a 
1.875% (range: 0.6%-4.875%) probability of surgical site infection). Surgical site infection 
attributable excess length of stay was the number of additional hospital days that patients with 
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surgical site infection stayed in the hospital postoperatively compared to patients with the same 
surgeries who did not acquire surgical site infections. 
Sensitivity analyses were conducted in order to determine the impact that varying 
efficacies and costs would have on the cost-effectiveness of the preoperative procedure. We 
systematically tested a wide range of chlorhexidine bath efficacies (10%, 25%, 50%, and 75%) 
and patient compliance rates (0.25*baseline compliance-2.00*baseline compliance) to evaluate 
variations from the baseline data found on Table 4.1 (mean compliance 15.3%, range 8.32%-
20.0%). We ran additional simulations varying patient age (53-63 years old), chlorhexidine cloth 
costs ($10.00-$100.00), SSI attributable excess length of stay (5 days-15 days), cost per bed day 
($3,000-$10,000), and probability of surgical site infection without implementation of the 
bathing intervention.  
4.4 RESULTS 
When the model was run at the baseline cost scenario (i.e., mean cost $29.35, standard 
deviation $7.89), distribution of preoperative bathing kits was the economically dominant 
strategy when cloth efficacy was ≥10% and compliance was ≥1.5x the baseline distribution; 
≥25% cloth efficacy and ≥75% the baseline compliance distribution; and ≥50% cloth efficacy 
and ≥50% the baseline compliance distribution. Chlorhexidine cloth cost, length of stay, patient 
compliance rates, and cloth efficacy were the most significant drivers to the model’s outcomes. 
Patient age (53-63 years old) and cost per bed day ($3,000-$10,000) did not substantially affect 
model outcomes and are not presented. When the probability of surgical site infection without 
implementation of the bathing intervention was ≤0.015 and compliance was equal to the baseline 
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distribution, distribution of kits was never cost-effective. When the probability of infection was 
1.75%, distribution of preoperative bathing kits was the dominant strategy when cloth efficacy 
was ≥75%. Distribution of bathing kits was also the dominant strategy when the probability of 
SSI was ≥2.0% and the cloth efficacy was ≥50%. 
4.4.1 Cost of Chlorhexidine Cloths 
Table 4.2 shows the results from our analysis. As the cost of the chlorhexidine cloths was 
increased from the baseline value to $100, the preoperative cloth became highly cost-ineffective 
at most compliance values and cloth efficacies. At this relatively high cost, distributing the 
preoperative bathing kits was the dominant strategy only when cloth efficacy was ≥75% and 
patient compliance was ≥75% of the baseline (mean: 11.48%); cloth efficacy was ≥50% and 
compliance was at least the baseline distribution (i.e., 15.3% (range: 8.23%-20.0%)); and with 
cloth efficacy ≥25% and twice the baseline compliance rate (mean: 30.6%).  When the cost of 
the cloths was decreased to $10 from the baseline rate of 29.35 (±7.89), preoperative bathing 
became the dominant strategy for all scenarios with efficacy ≥10% and compliance ≥50% of the 
baseline (mean: 7.65%). An increase in cloth cost to $50 varied little from baseline results. 
4.4.2 Excess Length of Stay Attributable to SSI 
Table 4.3 shows the results from our analysis. As the excess length of stay attributable to 
SSI for patients was increased from the baseline value of 9.5 days (range: 7.7-11.7 days) to 15 
days, the distribution of preoperative bathing kits became dominant at all patient compliance 
rates when cloth efficacy was at least 25%. When the duration of excess stay was equal to 15 
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days and cloth efficacy was 10%, the bathing strategy was dominant as long as patient 
compliance was at least 75% of the baseline value (mean: 11.48%). When the length of stay for 
patients was decreased from the baseline value (mean: 9.5 days) to 5 days, the kit distribution 
became dominant in fewer scenarios, specifically at 25% cloth efficacy. Extending the length of 
stay from the baseline value to 15 days seemed to have a greater impact on the model’s outcomes 
than did decreasing the length of stay. 
4.4.3 Patient Compliance with Bathing 
Although cost and length of stay affected the model’s outcomes, patient compliance rates 
had the greatest impact on results. At baseline compliance (i.e., 15.3% (range: 8.23%-20.0%)), 
the chlorhexidine cloth was dominant in all simulated runs, as long as chlorhexidine cloth 
efficacy was ≥50%. When patient compliance values were reduced to ≥50% of baseline, a mean 
of 7.65%, and chlorhexidine cloth costs were no greater than $50, the chlorhexidine bathing 
strategy was dominant, as long as the chlorhexidine cloth efficacy was 50%. Even when patient 
compliance was lower than 50% of baseline (mean: <7.65%), the bathing strategy continued to 
be the dominant strategy at high cloth efficacy. When patient compliance was doubled, the 
chlorhexidine bath strategy was dominant in the simulated runs across the range of sensitivity 
analysis values, as long as chlorhexidine bath efficacy was ≥25%.  
4.4.4 Avoided Infections 
Figure 4.2 presents a graphical representation of the modeled number of infections 
avoided per thousand preoperative patients that the cloths are distributed to. At baseline patient 
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compliance (i.e., 15.3% (range: 8.23%-20.0%)) and 25% chlorhexidine cloth efficacy, 1.28 SSIs 
were avoided per thousand kits distributed. This increased to 2.26 infections avoided at 50% 
efficacy. When compliance was half of baseline compliance (mean: 7.65%), the number of SSIs 
avoided dropped to 1.23 at cloth efficacy of 50%. When patient compliance was double the 
baseline value and cloth efficacy remained at 50%, the number of infections avoided climbed to 
4.7. 
4.4.5 Bath Interventions 
Table 4.4 shows the number of bathing kits that need to be dispensed to prevent one SSI, 
and Figure 4.3 presents a graphical representation of the data. When cost and length of stay was 
held at baseline, which for cost was $29.35 (±$7.89) and length of stay was 9.5 days (7.7-11.7 
days), the number of kits that need to be distributed to prevent one SSI was calculated. As patient 
compliance increased, the absolute number of patients who needed to be prescribed a 
chlorhexidine bathing kit decreased. When compliance was a quarter of baseline (mean: 3.83%), 
the difference in number of bathing interventions was 5,841. When compliance was doubled 
from baseline (mean: 40%), the difference dropped to 678.  
4.4.6 Cost-Effectiveness Scatter Plot 
Figure 4.4 shows a cost-effectiveness scatter plot when patient compliance in applying 
the preoperative bath was the baseline distribution, the bath effectiveness was 90%, and 
preoperative bath cost was the baseline distribution. Each point represents the average of a 
thousand trials that were conducted for each modeled individual. Blue dots represent those 
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individuals who were randomized to the bathing intervention while red dots represent individuals 
who received only standard preoperative care and did not receive preoperative baths. The cost 
associated with individuals who received the preoperative bath tended to be higher, but they also 
tended to have higher effectiveness values. 
4.4.7 Relative Risk of Surgical Site Infections 
Figure 4.5 illustrates the relative risk of surgical site infection versus bathing compliance 
for various bath efficacy scenarios. As patient compliance increased, the relative of risk of 
surgical site infection with preoperative bathing decreased. Additionally, as the efficacy of the 
preoperative bath increased, the relative risk of surgical site infection with preoperative bathing 
also decreased. When bathing was 75% effacicious in preventing surgical site infections and 
patient compliance was the baseline distribution (mean: 0.153, range: 0.0823-0.200), the relative 
risk of SSI was 0.89. Increasing patient compliance to 1.5 times the baseline distribution the 
realtive risk decreased to 0.83, and as patient compliance increased to 2 times the baseline 
distribution the relative risk decreased to 0.78.  
4.5 DISCUSSION 
 
A recent study estimated that the cost of preventable SSIs in U.S. is estimated to be $166 
million to $345 million.166 Our model demonstrates that home-based preoperative bathing with 
chlorhexidine impregnated cloths is a cost-effective strategy across a wide range of antimicrobial 
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efficacy and patient compliance values. The intervention remains cost effective even for fairly 
low cloth efficacies and patient compliance values. For bathing to remain the economically 
dominant strategy cloth efficacy can be as low as 10%, as long as patient compliance was 
doubled from baseline to a mean value from a previous study to 30.60% (range: 16.46%-
40.00%). Conversely, patient compliance can be as low as half of the baseline value (i.e., 7.65% 
(range: 4.16%-10.00%)) as long as cloth efficacy was 75%. The patient compliance/cloth 
efficacy pair was impetus of the economic value of preoperative chlorhexidine bathing.  
To date, most of the opposition to home-based preoperative chlorhexidine bathing has 
emerged from concerns about low cloth antimicrobial efficacy and patient compliance. However, 
our study suggests these concerns may not be as crucial as initially thought. Although the 
Cochrane Collaboration’s 2009 systematic review assessing the effectiveness of preoperative 
bathing suggested that preoperative bathing with chlorhexidine was not an effective measure in 
the prevention of SSIs; this review did not include studies using a relatively new chlorhexidine 
cloth application.158, 161 The non-woven polyester fiber cloth, unlike traditional cotton 
washcloths, results in higher skin surface concentration of chlorhexidine associated with a 
greater antimicrobial effect.159 Since our study assumed that patients would receive other 
standard SSI prevention (i.e., prophylactic antibiotics, proper hair removal, surgical site 
preparation, etc.) our results suggest that there is additional value in including the distribution of 
preoperative home-based bathing kits into the package of surgical site prevention techniques 
used by surgeons. 
A recent study by Kassakian and colleagues evaluated the impact of daily bathing with 
2% chlorhexidine gluconate versus bathing with soap and water.167 This quasi-experimental 
study evaluated a primary outcome of the incidence of MRSA in non-ICU patients. There were 
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three distinct study periods: 1. January 1, 2008-December 31, 2008 was the control group of the 
baseline bathing practice using soap and water. 2. January 1, 2009-January 31, 2009 was the 
wash-in period that included training for implementing chlorhexidine bathing. 3. February 1, 
2009-March 31, 2010 was the experimental period during which all patients were bathed daily 
with chlorhexidine gluconate impregnated cloths. The rate of MRSA and vancomycin resistant 
enterococci (VRE) in the control group was 0.57 per 1,000 at risk patient days with 20 total 
cases, while the intervention group had a lower infection rate of 0.28 per 1,000 at risk patient 
days (10 cases, P=0.06).167 Using a Cox proportional hazards regression model, the investigators 
concluded that chlorhexidine bathing had a 0.36 (95% CI: 0.2-0.8) hazard compared to the 
reference group of traditional soap and water bathing (P=0.01). This study highlights the 
potential utility of chlorhexidine bathing as an infection prevention strategy that may be used in 
addition to preoperative home-based bathing. 
4.5.1 Limitations 
All computer simulation models are simplifications of real life scenarios and cannot 
represent all possible situations and outcomes. Our data inputs came from existing literature that 
explored the implementation of the chlorhexidine cloths as a SSI prevention technique and 
sensitivity analyses was performed to assess the robustness of the results. Additional clinical 
studies may further explore the impact of home-based preoperative chlorhexidine bathing and 
could be used to update our model in the future. 
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4.5.2 Conclusions 
Surgical site infections have substantial preventable morbidity, mortality, and cost.  Our 
model suggests that routine dispensing of home-based preoperative chlorhexidine bathing would 
have substantial economic value throughout a wide range of patient compliance levels, cloth 
efficacies, cloth costs, and SSI attributable lengths of hospital stay.  Implementing preoperative 
home-based bathing could decrease the number of reasonably preventable surgical site infections 
in the U.S. Our study supports the distribution of chlorhexidine cloths for preoperative bathing; 
this intervention remains cost-effective over a wide range of cloth efficacy and patient 
compliance values. 
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4.6 FIGURES AND TABLES 
 
Figure 4.1: Model Structure 
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Figure 4.2: Patient Compliance Rate versus Number of Infections Avoided Per Thousand 
Bathing Kits Distributed 
 
**Baseline Data is a triangular distribution with a mean value of 15.3% and a range of 8.23%-
20.0% 
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Figure 4.3: Patient Compliance Rate versus Number of Bathing Kits Distributed to Prevent 1 
Surgical Site Infection 
 
**Baseline Data is a triangular distribution with a mean value of 15.3% and a range of 8.23%-
20.0% 
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Figure 4.4: Cost-Effectiveness Scatter plot 
Each blue dot is a single trial where preoperative chlorhexidine bathing was 
implemented, and each red dot represents a single trial where preoperative chlorhexidine bathing 
was not implemented. The y-axis illustrates the ranging costs associated with each trial and the 
x-axis illustrates the ranging effictveness values, measured in QALYs. Note: in these simulations 
the difference in QALYs ranged from approximately 0.8398 to 0.84. 
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Figure 4.5: Relative Risk of Surgical Site Infection versus Bathing Compliance for Various Bath 
Efficacy Scenarios 
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Table 4.1: Model Input Parameters 
Description (Units) Mean 
Standard Deviation 
or Range 
Source 
Costs ($U.S.)    
Chlorhexidine Wipes 29.35 ±7.89 168-174 
Probabilities    
Compliance 0.153 0.0823 – 0.200 160-161 
Surgical Site Infection without Bath 0.025 0.008 – 0.065 160-161 
Time    
Infection (LOS) – Difference 9.5 7.7 – 11.7 155 
Effectiveness    
Age 63 QALY Value 0.84 - 128 
Orthopedic SSI QALY Value 0.90 - 124 
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Table 4.2: Cost-Effectiveness of Chlorhexidine Bath based on Cloth Cost 
Cloth 
Cost Compliance Rate† 
Bath Efficacy in Preventing Surgical Site 
Infections 
  10% 25% 50% 75% 
$10.00     
 ¼ of Baseline Compliance > 1 million+ Dominant* Dominant* Dominant* 
 ½ of Baseline Compliance Dominant* Dominant* Dominant* Dominant* 
 ¾ of Baseline Compliance Dominant* Dominant* Dominant* Dominant* 
 Baseline Compliance Dominant* Dominant* Dominant* Dominant* 
 1.5x Baseline Compliance  Dominant* Dominant* Dominant* Dominant* 
 2x Baseline Compliance Dominant* Dominant* Dominant* Dominant* 
Baseline Cost     
 ¼ of Baseline Compliance > 1 million+ > 1 million+ > 1 million+ > 1 million+ 
 ½ of Baseline Compliance > 1 million+ > 1 million+ Dominant* Dominant* 
 ¾ of Baseline Compliance > 1 million+ Dominant* Dominant* Dominant* 
 Baseline Compliance > 1 million+ Dominant* Dominant* Dominant* 
 1.5x Baseline Compliance  Dominant* Dominant* Dominant* Dominant* 
 2x Baseline Compliance Dominant* Dominant* Dominant* Dominant* 
$50.00     
 ¼ of Baseline Compliance > 1 million+ > 1 million+ > 1 million+ > 1 million+ 
 ½ of Baseline Compliance > 1 million+ > 1 million+ Dominant* Dominant* 
 ¾ of Baseline Compliance > 1 million+ > 1 million+ Dominant* Dominant* 
 Baseline Compliance > 1 million+ Dominant* Dominant* Dominant* 
 1.5x Baseline Compliance  > 1 million+ Dominant* Dominant* Dominant* 
 2x Baseline Compliance > 1 million+ Dominant* Dominant* Dominant* 
$100.00     
 ¼ of Baseline Compliance > 1 million+ > 1 million+ > 1 million+ > 1 million+ 
 ½ of Baseline Compliance > 1 million+ > 1 million+ > 1 million+ > 1 million+ 
 ¾ of Baseline Compliance > 1 million+ > 1 million+ > 1 million+ Dominant* 
 Baseline Compliance > 1 million+ > 1 million+ Dominant* Dominant* 
 1.5x Baseline Compliance  > 1 million+ > 1 million+ Dominant* Dominant* 
 2x Baseline Compliance > 1 million+ Dominant* Dominant* Dominant* 
†Baseline compliance refers to a mean compliance value of 15.3% (range 8.23-20.0%).  
> 1 million+ refers to the model’s calculated ICER value. The value is greater than 1 million   
   dollars, which is much greater than the $50,000 cost-effectiveness threshold.76 
Dominant* signifies that the distribution of preoperative bathing kits is dominant over the no bath  
    strategy. It is both less costly and more effective than no preoperative bath. 
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Table 4.3: Cost-Effectiveness of Chlorhexidine Bath Based on Excess Length of Stay 
Attributable to Surgical Site Infection 
SSI 
attrib. 
excess 
LOS Compliance Rate† Bath Efficacy in Preventing Surgical Site Infections 
  10% 25% 50% 75% 
5 Days      
 ¼ of Baseline Compliance > 1 million+ > 1 million+ > 1 million+ > 1 million+ 
 ½ of Baseline Compliance > 1 million+ > 1 million+ Dominant*  Dominant*  
 ¾ of Baseline Compliance > 1 million+ > 1 million+ Dominant*  Dominant*  
 Baseline Compliance > 1 million+ > 1 million+ Dominant*  Dominant*  
 1.5x Baseline Compliance  > 1 million+ Dominant* Dominant*  Dominant*  
 2x Baseline Compliance Dominant*  Dominant*  Dominant*  Dominant*  
Baseline Length of Stay     
 ¼ of Baseline Compliance > 1 million+ > 1 million+ > 1 million+ > 1 million+ 
 ½ of Baseline Compliance > 1 million+ > 1 million+ Dominant*  Dominant*  
 ¾ of Baseline Compliance > 1 million+ Dominant*  Dominant*  Dominant*  
 Baseline Compliance > 1 million+ Dominant*  Dominant*  Dominant*  
 1.5x Baseline Compliance  Dominant*  Dominant*  Dominant*  Dominant*  
 2x Baseline Compliance Dominant*  Dominant*  Dominant*  Dominant*  
15 Days     
 ¼ of Baseline Compliance > 1 million+ Dominant*  Dominant*  Dominant*  
 ½ of Baseline Compliance > 1 million+ Dominant*  Dominant*  Dominant*  
 ¾ of Baseline Compliance Dominant*  Dominant*  Dominant*  Dominant*  
 Baseline Compliance Dominant*  Dominant*  Dominant*  Dominant*  
 1.5x Baseline Compliance  Dominant*  Dominant*  Dominant*  Dominant*  
 2x Baseline Compliance Dominant*  Dominant*  Dominant*  Dominant*  
†Baseline compliance refers to a mean compliance value of 15.3% (range 8.23-20.0%).  
> 1 million+ refers to the model’s calculated ICER value. The value is greater than 1  
    million dollars, which is much greater than the $50,000 cost-effectiveness threshold.76 
Dominant* signifies that the distribution of preoperative bathing kits is dominant over the  
    no bath strategy. It is both less costly and more effective than no preoperative bath. 
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Table 4.4: Number of Bathing Kits that Need to be Dispensed to Preoperative Patients to 
Prevent One Surgical Site Infection 
Compliance Rate† Bath Efficacy 
 10% 25% 50% 75% 
¼ of Baseline Compliance 7,042 2,434 2,370 1,201 
½ of Baseline Compliance 4,220 2,198 817 499 
¾ of Baseline Compliance 2,273 1,311 579 364 
Baseline Compliance 1,191 780 443 269 
1.5x Baseline Compliance  1,101 700 269 185 
2x Baseline Compliance 815 364 212 137 
†Baseline compliance refers to a mean compliance value of 15.3% (range 8.23-20.0%).  
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5.0  GENERAL DISCUSSION AND PUBLIC HEALTH IMPORTANCE 
Substantial preventable morbidity and mortality due to nosocomial infections occurs each 
year in the United States and worldwide. The World Health Organization estimates that 
worldwide daily number of prevalent nosocomial infections is more than 1.4 to 1.7 million.1, 79 
Surveillance and isolation of those who test positive for MRSA can prevent a substantial number 
of secondary cases of MRSA. With rapid turnaround time, surveillance has the potential to 
prevent infections and also affords economic benefits. Adding home-based chlorhexidine bathing 
cloth kits to a suite of pre-operative care for orthopedic patients can surgical site infections and 
associated mortality.  
A multifaceted program of nosocomial infection prevention has the potential to both 
improve patient outcomes and save third party payers money. Testing adult patients in general 
medical wards has the potential to prevent nosocomial transmission of MRSA among patients in 
the hospital. However, policy makers and hospital administrators must carefully consider the 
attributes of the diagnostic test used in a screening program. Increasing the number of anatomic 
sites tested with surveillance cultures does not appear to have as great an impact as decreasing 
turnaround time on the ultimate economic value of a MRSA testing strategy. Hospital infection 
control personnel could use the models described here to help benchmark the test characteristics 
to be used in their local infection prevention programs. 
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Weekly surveillance of all neonates in the NICU and isolation of those who test positive 
is a second technique that hospitals could use to decrease the incidence on nosocomial infections. 
Asymptomatic neonates can be colonized with S. aureus on their skin, umbilicus, nares, and 
perineum. When outbreaks of MRSA have occurred in the NICU surveillance has been utilized 
as a central component of the infection control strategy.131, 134, 136 Hospitals with moderate to 
high adherence to isolation protocols have the potential to prevent morbidity and mortality 
among neonates in the NICU. Understanding the economic and epidemiologic impact of 
different neonatal MRSA surveillance strategies will help enable decision makers when 
designing nosocomial infection prevention strategies. 
At least 1 in every 100 procedures is complicated by a SSI during their hospital stay, 
making prevention of postoperative nosocomial infections an area of great promise for 
decreasing the overall burden of nosocomial infections. Our model evaluated the economic and 
epidemiologic value of distributing home-based preoperative bathing kits to patients and 
concluded that the distribution of preoperative bathing kits is cost-effective across a wide range 
of patient compliance and bath efficacy values. Moreover, the distribution of these kits is 
economically dominant saving costs and preventing adverse health outcomes for patients 
postoperatively.   
The joint statement issued by the Society for Healthcare Epidemiology of America 
(SHEA), the Association for Professionals in Infection Control and Epidemiology (ACIP), the 
Pediatric Infectious Disease Society (PIDS), the Infectious Disease Society of America (IDSA), 
the Council of State and Territorial Epidemiologists (CSTE), the Association of State and 
Territorial Health Officials (ASTHO), and the CDC called for the elimination of healthcare 
associated infections.68-69 Surveillance and isolation of those who test positive for pathogens 
 78 
such as MRSA have the potential to eliminate intra-hospital transmission, decreasing morbidity 
and mortality. Implementation of preoperative care bundles precludes surgical site infections. A 
multifaceted approach including the surveillance test characteristics, target populations, and 
interventions modeled here will help move towards the elimination of healthcare acquired 
infections.  
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